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1. INTRODUCTION 
“The important thing in science is not so much to obtain new 
facts as to discover new ways of thinking about them.” 
˜Sir William Bragg˜ 
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1.1. THE PROCESS OF ANGIOGENESIS 
The formation of new blood vessels is subdivided into vasculogenesis and 
angiogenesis. Vasculogenesis is the formation of blood vessels de novo, in the 
absence of any pre-existing vascular system, from endothelial cell precursors called 
hemangioblasts. In vasculogenesis the endothelial cell precursors proliferate and 
migrate into avascular areas starting to form a primitive tubular network. These 
hemangioblasts later differentiate into endothelial cells 1-3. This process was until 
recently believed to only occur during embryogenesis. However, new findings show 
that endothelial precursor cells exist in the bone marrow in adults 4 and it has further 
been shown in animal models that they are able to participate in both physiological 
and pathological neovascularization 5. These findings indicate that vasculogenesis 
not only occurs in the early embryo but also contributes to new vessel formation in 
adults. 
 
Once the primary vessel plexus has been formed, it is remodelled. Vessels fuse to 
form larger vessels or divide to create a network of smaller vessels. This sprouting of 
endothelial cells from already existing vessels to further expand the vascular tree is 
referred to as angiogenesis and occurs not only in the embryo but is repeated many 
times in the adult during wound healing and the reproductive cycle 1-3. In addition to 
the angiogenesis belonging to daily life, several pathological conditions can induce 
this process, such as tumour growth, ischemia, chronic inflammatory diseases and 
diabetic retinopathy 6,7. 
 
Angiogenesis is a complicated highly regulated process dependent on the interplay 
and balance between several angiogenic and anti-angiogenic factors favouring or 
inhibiting angiogenesis respectively. Angiogenesis is comprised of different steps, as 
pointed out below, such as vasodilation and permeability of the already existing 
vessel, vessel destabilization and matrix degradation, endothelial cell proliferation 
and migration and finally lumen formation and vessel stabilization. Figure 1.1 
contains a summarized description of the angiogenesis process and the factors 
influencing it.  
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Vasodilation and endothelial permeability 
Vasodilation of the pre-existing blood vessel initiates angiogenesis and is mediated 
by nitric oxide (NO) which stimulates the relaxation of the smooth muscle cells 
surrounding the vessel by the formation of cyclic guanosine monophosphate 
(cGMP) 8. To increase the permeability of endothelial cells, intercellular clefts and/or 
vesiculo-vacuolar organelles (VVO) are formed. The latter are grape like clusters of 
vesicles and vacuoles which can span from the luminal to the abluminal side of the 
plasma membrane. Both mechanisms permit macromolecules, such as fibrinogen 
and plasminogen, to pass through the endothelial layer 9. The extravasation of these 
molecules constitutes a temporary framework for the later migrating endothelial cells. 
Both vasodilation and increased permeability are induced and initiated by vascular 
endothelial growth factor (VEGF), thus being the most critical factor for vessel 
formation 10-12. 
 
Vessel destabilization and matrix degradation 
To allow for endothelial cells to sprout from the existing vessel, the mature vessel 
needs to be destabilized. For this the intercellular and pericellular contacts need to 
be disrupted.  Angiopoetin 2 may be of importance here by detaching the 
surrounding smooth muscle cells or pericytes and by loosening the matrix 8. Further, 
the endothelial cell basement membrane must be degraded and the perivascular 
stroma has to be remodelled. This is achieved by different proteinase members of 
the plasminogen activator, matrix metalloproteinases, chymase and heparanase 
families. The endothelial cells secrete most of these extracellular matrix (ECM) 
degrading enzymes upon growth factor stimulation, such as VEGF and basic 
fibroblast growth factor (bFGF) 13. The degradation of the ECM also releases growth 
factors such as bFGF, VEGF and insulin growth factor 1 (IGF-1) further stimulating 
angiogenesis 2,8.   
 
Endothelial cell proliferation and migration 
Once the path has been cleared, proliferating endothelial cells migrate into the 
remodelled perivascular space along a chemotactic gradient established by 
angiogenic growth factors. Important factors driving proliferation and migration are 
members of the VEGF- and FGF family, epidermal growth factor (EGF), insuline like 
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growth factor 1 (IGF-1), angiopoetin 1 and 2 (Ang1 and 2), angiogenin, the integrins 
αvβ3 and α5β3 and C-X-C chemokines (chemokines with paired cysteines, C, 
separated by a different amino acid) such as interleukin 8 (IL-8). Whereas VEGF and 
the angiopoetins are specific for the endothelium, the other proangiogenic factors can 
also induce proliferation and migration of other cell types 2. 
 
Tube formation and vessel stabilization 
When the endothelial cells have reached the site of supposed neovascularization, 
they organize themselves into a monolayer to form tube-like structures. By 
intercalation and thinning of the endothelial cells and fusion of already existing 
vessels, the new vessel increases its diameter and length 2,8. Some isoforms of 
VEGF and Ang1 combined with VEGF are responsible for the increase of lumen 
diameter. Essential factors for endothelial cells to adhere to each other and so 
extending the new vessel are cell surface receptors such as the endothelial cell 
adhesion molecule (PECAM-1) and vascular endothelial (VE)-cadherin 1. The 
formation of tube-like structures is not only regulated by different growth factors, 
adhesion molecules and their respective receptors but also by the extracellular matrix 
(ECM). Whereas endothelial cells grown on collagen in two-dimensional (2D) culture 
dishes are in a proliferative state, endothelial cells grown in a three-dimensional (3D) 
collagen gel seize to proliferate and exhibit a more differentiated phenotype to finally 
form tube-like structures 14,15. The integrin family is one of many to mediate cell-
extracellular matrix interactions and function as receptors for the ECM on endothelial 
cells to promote cell motility or maintain vascular stability 16. The integrins αvβ3, which 
is a vitronectin receptor, and α1β1, a collagen receptor, are examples of integrins 
involved in lumen formation 2,3,17. Once the endothelial cells have interconnected this 
network needs to be strengthened. This is accomplished by the basement membrane 
laminin-binding integrins such as α6β1 and α3β1 17. Finally, the premature vessel 
needs to be further stabilized. For this mesenchymal cells proliferate and migrate 
along the newly formed endothelial tube where they then differentiate into pericytes 
(lining small vessels) or smooth muscle cells (lining larger vessels) 2,3,13. Angiogenic 
factors inducing these mechanisms are platelet derived growth factor BB (PDGF-BB), 
angiopoetin 1 and VEGF. VEGF contributes probably not only by inducing VEGF 
dependent cell signalling but also by stimulating the release of PDGF thereby 
recruiting mural cells. This recruitment is also promoted by tissue factor. Ang1 
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stabilizes the interaction between mural cells and the endothelial tube and induces 
branching 8. Another important agent is tumour necrosis factor β (TGFβ), which 
inhibits endothelial cell growth and migration thereby enabling stabilization and 
maturation of the vessel. In addition, TGFβ controls the differentiation of vascular 
smooth muscle cells and stimulates new extracellular matrix production to further 
strengthen the interaction between endothelial and mural cells 2,3,8,13. Other factors 
stimulating this process include heparin-binding epidermal-growth-factor like factor 
and endothelin-1. 
1.Vessel destabilization
Ang2/Tie2
2. Vessel hyperpermeability
VEGF, VE-Cadherin
Matrix remodelling
TGF-ß
3. EC proliferation
VEGF, EGF, FGF
Ang2/Tie2
Ang1/Tie2
4. EC migration
avß3 integrin
VEGF, FGF 5. Cell:cell contact
VE-Cadherin
Ephrin B2/eph B4
6. Tube formation
FGF, VEGF, PDGF
TNF-a, Eph-2A
9. Vessel stabilization
Ang1/Tie2
VE-Cadherin
TGF-ß
VEGF, PDGF
8. Pericyte differentiation
TGF-ß
7. Mesenchymal
proliferation/migration
PDGF
Ang1/Tie2
Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. 
Am J Physiol Cell Physiol. 2002;282:C947-C970.  
 
 
Fig. 1.1 The process of angiogenesis 
Angiogenesis is initiated by vessel dilation, permeabilisation and destabilization. This 
is followed by proliferation of endothelial cells, which migrate into the avascular 
space where they form cell-cell contacts for subsequent tube formation. Finally the 
new vessels become stabilised by pericytes or smooth muscle cells. This process is 
influenced by different factors.  
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1.1.1. VEGF and angiogenesis 
In 1983 Senger et al. identified a 34-42 kDa protein in tumour ascites fluids from 
guinea pigs that increased microvascular permeability. This protein was named 
tumour vascular permeability factor (VPF) 18. In 1989 Ferrara et al reported the 
finding of a growth factor having mitogenic effects exclusively on endothelial cells. 
The factor was therefore named vascular endothelial growth factor (VEGF) 19. Later 
the same year, cloning of both VPF 20and VEGF 21 revealed that it was the same 
protein. Meanwhile the human VEGF family is known to consist of VEGF-A, -B, -C, -
D, and placental growth factor (PlGF). The members of the VEGF-family are dimeric 
glycoproteins belonging to the platelet derived growth factor (PDGF) superfamily and 
bind with different affinities to three related receptor tyrosine kinases: VEGF receptor 
1 (VEGFR-1 or Flt-1), VEGF receptor 2 (VEGFR-2 or KDR) and VEGF receptor 3 
(VEGFR-3 or Flt-4). VEGF-A binds to VEGFR-1 and -2 as well as to receptor 
heterodimers. VEGF-A also binds to Neuropilin-1, a neuronal receptor for the 
collapsin/semaphorin family also expressed on endothelial cells. Neuropilin-1  
interacts with VEGFR-2 and thus enhances the binding of VEGF-A to VEGFR-2 22,23. 
VEGF-B and PlGF only bind VEGFR-1, while VEGF-C prefers binding to VEGFR-2 
and-3. Although VEGFR-1 is more abundant in adult tissue and binds VEGF with a 
higher affinity than VEGFR-2 2, it has been shown that VEGFR-2 is mainly 
responsible for VEGF signalling 24. 
 
In contrast to the other VEGF isoforms, which seem to exhibit tissue specificities, 
VEGF-A is expressed in most organs in humans and at least five different isoforms of 
the human VEGF-A exist due to alternative splicing of a single pre-mRNA 2,7,13,22,24. 
The different isoforms are denoted after their amount of amino acids (VEGF121, 
VEGF145, VEGF165, VEGF189, VEGF206) and exhibit different signalling properties as 
well as different expression patterns. Isoforms consisting of 148, 162 and 183 amino 
acids have also been reported as well as the isoform VEGF-A165b which seems to 
have opposing effects to VEGF-A165.  VEGF-A145, VEGF-A189, VEGF-A206 are bound 
to the cell surface due to heparin-binding domains whereas VEGF-A121 and 
VEGF-A165 are diffusible. The latter two isoforms are the most abundant ones but 
VEGF-A165 seems to be the most potent promoting angiogenesis as it stimulates 
endothelial DNA synthesis and proliferation, has anti-apoptotic effects and induces 
endothelial cell migration. VEGF induced endothelial cell proliferation is mainly 
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mediated by the Ras-Raf-MEK-ERK pathway 2,24,25 but also by the formation of NO, 
while endothelial cell survival is maintained by activation of the PI3-Kinase/Akt 
pathway as well as through interaction with several integrins. Migration of endothelial 
cells upon VEGF stimulation is driven by p38-MAPK signalling, the focal adhesion 
kinase (FAK) and RhoA GTPase among others 24,25.  
 
VEGF has a prominent role in angiogenesis. Mice lacking a VEGF allele die in utero 
between day 11 and 12, probably due to defective vascularization 23,24. Deletion or 
mutation of VEGFR-2 is also embryonically lethal due to impaired development of 
both endothelial and hematopoietic cells and the complete absence of blood 
vessels 2,10,23,24. Deletion of VEGFR-1 leads to failure of formation of an organized 
vascular network. Interestingly, studies where the tyrosine kinase domain but not the 
intracellular domain of the VEGFR-1 was absent showed no defects in vessel 
formation. This led to the proposition that VEGFR-1 may compete with VEGFR-2 for 
substrate during angiogenesis and an inability to do so would lead to elevated levels 
of available VEGF for VEGFR-2 and so to an excessive VEGFR-2 signalling. This 
could be responsible for the impairment in normal vessel growth in the VEGFR-1 
knock-out model 2,10,23,24. VEGF is not only crucial for embryonic angiogenesis but it 
is also essential for angiogenesis in adults as administration of soluble VEGF 
receptors, which block VEGF signalling, in juvenile mice results in  suppression of 
blood vessel invasion into bone growth plates leading to reduced femur length 2,3. As 
mentioned earlier, VEGFR-1 does not seem to be the primary mediator of VEGF 
signalling during development. This may be due to its poor kinase activity and it has 
further been reported that only weak proliferative and migratory responses are 
mediated through this receptor. VEGFR-1 has recently been shown to be more 
important in pathological angiogenesis and wound healing by facilitating VEGFR-2 
signalling. VEGFR-2 on the other hand regulates endothelial cell proliferation, 
migration, differentiation, survival and increases vessel permeability and dilation 23.  
VEGFR-3 does not seem to be essential for the vasculogenesis in embryos, but is 
more important for the remodelling of the primitive vascular plexus as mice with a 
disrupted VEGFR-3 fail to remodel the plexus and die after day 9.5 due to cardiac 
failure. The receptor appears to be responsible for the formation of blood as well as 
for lymphatic vasculature in the embryo but is constricted to the lymphatic vessels in 
adults. In addition to the VEGFR-1-3, the VEGF receptor Neuropilin-1 also seems to 
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be essential for normal vessel formation as Neuropilin deficient mice show 
incomplete vessels and vascular network development 2 (For a schematic illustration 
of the role of VEGF in angiogenesis, see fig. 1.1). 
1.1.2. FGF and angiogenesis 
20 distinct fibroblast growth factors (FGF1-20) and four tyrosine kinase receptors 
(FGFR1-4) have been identified so far.  Among these 20 different FGFs, acidic FGF 
(aFGF) or FGF-1 and basic FGF (bFGF) or FGF-2 are the best described in 
angiogenesis. They are secreted from a variety of different cell types and can bind to 
all four receptors 2,26. bFGF has been shown to induce endothelial cell proliferation by 
binding mainly to the FGFR-1 thereby activating the MAPK pathway 25,27. Further it 
has been demonstrated that bFGF is important for endothelial cell migration and 
differentiation as well as for endothelial cell survival in combination with VEGF by 
activating the PI3-K pathway 28. In addition, bFGF has been shown to stimulate 
endothelial cells to form tube like structures in a 3D collagen matrix 13,29. Moreover, it 
was also observed that bFGF induced the production of urokinase-type plasminogen 
activator (u-PA) in endothelial cells, which relates well to the invasive properties of 
endothelial cells during angiogenesis 29. Further, bFGF increases the expression of 
αvβ3 integrins on endothelial cells 2,26 thereby probably facilitating migration. The 
VEGF expression is also upregulated by bFGF and it induces angiogenesis in the 
chicken chorioallantoic membrane (CAM) assay 28. Recently, it was shown that also 
aFGF  is capable of inducing sprouting of new vessels in the CAM assay 30,31. 
Astonishingly, vascular development is normal in mice deficient in aFGF and 
bFGF 2,13,26. On the other hand, wound repair seemed to be delayed in bFGF and 
bFGF/aFGF knock-out mice 2,26. FGFs are stored not only in endothelial cells but 
also in the ECM by binding to heparin. Mechanical injury disrupts the ECM and 
endothelial cells thus release bFGF. Mechanical force has also been proposed to 
stimulate the endothelium to release FGF. This suggests that FGF in vivo may be 
more important in angiogenesis in the context of tissue repair rather than in all 
angiogenic responses 13,26 (Fig. 1.1 shows the overall role of FGF in angiogenesis). 
 
1.1.3. PDGF and angiogenesis 
PDGF exist in homodimers (PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD) and 
heterodimers (PDGF-AB). The PDGF receptors exhibit different binding affinities 
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depending on the isoforms. PDGF-AA forms αα-receptor homodimers, PDGF-AB 
induce the formation of αα-receptor homodimers and αβ-receptor heterodimers. 
PDGF-BB is able to form all three compositions (αα, αβ and ββ) while PDGF-CC 
and –DD mainly form αα- and ββ-receptor homodimers 13,32. Whereas extensive 
research has been performed on VEGF and FGF in angiogenesis, less is known 
about the exact role of PDGF in this context. Capillary endothelial cells express 
PDGF β-receptors and PDGF-BB has been found to stimulate endothelial cell 
proliferation and tube formation in vitro 33 as well as to increase the vessel density in 
the chicken chorioallantoic membrane 34, whereas PDGF-AA seemed to elicit less 
angiogenic effects both in vitro and in vivo 33-35. The angiogenic potency of PDGF-BB 
is further strengthened by the finding that the movement of entire endothelial cord 
structures is increased when exposed to PDGF-BB 36. Blockage of the PDGF 
β-receptor in glomerular endothelial cells led to apoptosis, indicating a role for PDGF 
in endothelial cell survival 37. PDGF-B knock-out mice die during late gestation by an 
abnormal renal development and failure of pericytes to migrate to the new blood 
vessels. Finally, the role of PDGF in angiogenic processes is highlighted by its 
potency in mediating tumour angiogenesis. PDGF released from tumour cells 
stimulate the migration and proliferation of both vascular smooth muscle cells and 
endothelial cells. Furthermore, PDGF has been shown to also indirectly stimulate 
angiogenesis by inducing the transcription and secretion of VEGF 35. 
 
 
1.2. ANGIOGENIC PATHWAYS 
1.2.1. The PI3-Kinase pathway 
Anti-apoptotic signals are necessary for angiogenesis to occur. Normally, when cells 
are detached from the extracellular matrix, they undergo programmed cell death, 
apoptosis. This form of apoptosis which is induced by the lack of attachments to 
ECM is also called anoikis and preserves the organism from dysplastic growth of 
cells 38,39. During angiogenesis however, the ECM is degraded and the endothelial 
cells loose their attachments to the ECM without undergoing apoptosis. This is 
achieved by repression of the apoptotic signals by certain anti-apoptotic or cell 
survival signalling pathways. Not only is the anti-apoptotic effect important in this 
particular step of angiogenesis but it is vital through the whole angiogenic process as 
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well as for preservation of the quiescent endothelium preventing vascular regression. 
There are several factors promoting cell survival and thus inhibiting apoptosis, such 
as the survival factors bFGF and VEGF, NO, integrin-adhesion to the ECM and 
interendothelial connections through VE-Cadherin. They all transduce their signals 
through different intracellular signalling molecules but almost all of the signalling 
pathways activated seem to merge at one point, they induce the activation of the 
phosphoinositide 3-Kinase (PI3-Kinase)/Akt pathway.  However, the PI3-Kinase/Akt 
pathway not only suppresses apoptosis but also promotes cell proliferation as well as 
migration and is involved in vesicular trafficking, differentiation and cytoskeletal 
rearrangements 33,40. 
 
In mammals there are three classes of PI3-kinases, namely class I, class II and class 
III based on their structures and substrate specificity (for a more detailed description 
of the different members of the three classes, see fig. 1.2). The best studied group is 
the class I, which is further divided into class IA and IB. The members of these 
classes phosphorylate phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) thereby 
producing phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3). The class IA and IB 
enzymes all form heterodimeric complexes consisting of a catalytic subunit of 110-
120 kDa and a non catalytic regulatory subunit or adaptor of 55 or 85 kDa.  The class 
I catalytic subunits include p110α, -β, -δ and -γ and all, except p110γ, contain a p85 
subunit binding domain at the N-terminus. They further contain a Ras binding 
domain, a phosphoinositide kinase domain and a C-terminal catalytic domain 41. 
They all exhibit serine/threonine protein kinase activity used to phosphorylate the 
regulatory subunit p85 on a serine residue. This phosphorylation decreases 
PI3-Kinase activity 41-43. Whereas the p110α and -β are ubiquitously expressed, the 
p110δ is predominantly expressed in leucocytes and the p110γ is found in pancreas, 
skeletal muscle, liver and heart. The regulatory subunits of the class IA are encoded 
by at least three different genes which give rise to three isoforms p85α, -β and 
p55 γ 41,44. The subunits p85α and -β contain two Src- homology 2 (SH2) domains 
which allow the subunit to bind to phospho-tyrosines. Interaction with p110 is 
mediated by the region situated between the two SH2 domains. In addition they 
exhibit a Src- homology 3 (SH3) domain at the N-terminus directing protein 
interaction to polyproline motif regions 40,41,45. The class IB regulatory subunit is a 
97 kDa protein called p101 41. It is the regulatory subunit that controls the recruitment 
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of PI3-Kinase to the membrane, enabling it to associate with membrane associated 
signalling complexes, and brings it close to its lipid substrate 41,44.  In quiescent cells 
the degradation of the p110 subunit is prevented and the lipid kinase activity is 
inhibited by the regulatory subunit. This suppression is relieved when the SH2 
domains of p85 bind tyrosine phosphorylated proteins such as tyrosine kinase 
receptors or receptor adaptor proteins with the amino acid sequence pTyr-X-X-
Met 40,41. Recently it has been shown that tyrosine phosphorylation of the p85 subunit 
on Tyr688 by Src kinases also alleviate the inhibitory effect of p85 on p110 thus 
regulating PI3-Kinase activity 40,46. A negative regulator of p85 has also been 
identified, the Src homology domain 2 containing tyrosine phosphatase 1 (SHP-1). It 
has been shown to bind to tyrosine phosphorylated p85 and expression of a 
phosphatase inactive form of SHP-1 increases PI3-Kinase activity 40. 
 
Class Catalytic subunit Schematic representation Substrate 
specificity 
Adaptor/ 
Binding partner 
IA 
 
IB 
p110α 
p110β 
p110δ 
 
p110γ 
  
PtdIns, 
PtdIns (4)P, 
PtdIns(4,5)P2 
p85α 
p85β 
p55γ/p55PIK 
 
p101 
II PI3-K-C2α/ 
mcpk/p170 
PI3-K-C2β 
PI3-K_68D/cpk 
 PtdIns, 
PtdIns (4)P 
(PtdIns(4,5)P) 
 
Unknown 
III Vps34p/ 
PtdIns 3-kinase 
 
PtdIns Vps15p/p150 
 
Fig. 1.2 Classification of mammalian PI3-Kinase family members 
The catalytic subunits are divided into classes according to the sequence homology 
of the catalytic domain between the subunits. p55PIK is specific for mouse, whereas 
p55γ is bovine. The Class III consists of the PI3-Kinase yeast homologue (Vps34p).  
 
 
Domin J, Waterfield MD. Using structure to define the function of 
phosphoinositide 3-kinase family members. FEBS Lett. 1997;410:91-95.
p85 binding
Ras binding
PIK binding
Kinase domain
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C2 domain
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Active PI3-kinase produce PI(3,4,5)P3 to which Akt, a serine/threonine protein kinase 
also referred to as protein kinase B (PKB), bind thereby recruiting Akt to the 
membrane. Akt is then subsequently phosphorylated at a serine and a threonine 
residue by 3-phosphoinositide-dependent protein kinase 1 and 2 (PDK1 and 2) to 
become fully active. In mammals three Akt isoforms exist: Akt 1, 2 and 3 whereof 
Akt 1 is highly expressed in endothelial cells. In cell survival, Akt exhibits a major role 
as a regulatory enzyme. For example, Akt inhibits proapoptotic proteins such as Bad, 
Bax and caspase-9 25,47. By inhibiting Bad, Akt also increases the amount of active 
Bcl-2 which is an anti apoptotic protein. By activating Inhibitor of nuclear factor 
kappa-B kinase (IKK) thereby favouring the dissociation of nuclear factor kappa-B 
(NFκB) from its inhibitor IκB leading to the nuclear translocation of NFκB and 
transcription of anti-apoptotic proteins such as the inhibitor of apoptosis proteins 
(IAPs) Akt further promotes cell survival 25. Finally, Akt increases the production of 
NO by stimulating NO synthase 48,49. The NO produced is in turn involved in caspase 
inactivation47. 
 
As well as regulating cell survival in endothelial cells, the PI3-Kinase / Akt pathway 
also mediates endothelial cell migration. It is not fully clear how but several studies 
indicate that Akt is required for Rho family GTPases dependent migration by either 
activating Rac or by itself being activated by Rac and Cdc 42.  Both Rac and Cdc 42 
drive endothelial cell migration by inducing membrane ruffling, extension of 
lamellipodia and membrane protrusions 47. 
 
Several stimuli activate the PI3-Kinase / Akt pathway. Both VEGF and FGF have also 
been shown to influence endothelial migration 50,50,51 and DNA synthesis 50 through 
the PI3-Kinase/Akt pathway as well as angiogenesis in the chorioallantoic membrane 
(CAM) assay 50,51. Whereas very little is known about the precise signalling pathways 
initiated by the FGFs in endothelial cells, there are more studies involving VEGF in 
endothelial signalling. It has been demonstrated that VEGF together with integrin 
mediated adhesion to the ECM activates Akt. This leads to activation of the focal 
adhesion kinase (FAK) and the formation of focal adhesions thus preventing 
anoikis 25,47. The proliferative response to PI3-Kinase activation upon VEGF 
stimulation has been shown to be mediated by MAP kinase activation 45.  
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Fig. 1.3 Schematic illustration of the PI3-Kinase regulated pathways 
Many different stimuli have been shown to activate the PI3-Kinase, such as different 
growth factors, shear stress, ROS and sphingosine-1-phosphate (S1P). Most of the 
effects caused by a PI3-Kinase activation are transduced through Akt, but some have 
also been shown to be mediated by Raf. The different effects are stimuli specific.  
 
In addition to VEGF and FGF, PDGF can also activate PI3-Kinase. It has been 
shown that PI3-Kinase directly binds to phosphorylated tyrosines on the PDGF 
receptor (PDGFR) upon PDGF stimulation in fibroblasts 52. It has further been shown 
that the association between the PDGFR and PI3-Kinase is of high stoichiometry so 
that almost all available PI3-Kinase molecules are occupied by the receptor 53.  
Moreover, it has been established that the binding to the PDGFR is important for 
PI3-Kinase activity 53 and Akt activation 54 as well as for PDGF induced DNA 
synthesis 53. Experiments in fibroblasts and HepG2 cells with mutant PDGFR which 
cannot bind PI3-Kinase and which are unable to activate Ras showed that although 
the receptors bound PI3-Kinase they were unable to activate the enzyme. This led to 
the assumption that PDGF induced PI3-kinase activity not only depends on the 
receptor/PI3-Kinase complex but also on the activation of Ras 55. The exact role of 
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PDGF in PI3-Kinase/Akt signalling in endothelial cells remains to be elucidated (for a 
schematic illustration of the PI3-Kinase pathway in angiogenic signalling, see 
fig. 1.3). Other stimuli for activation of the PI3-Kinase / Akt pathway in endothelial 
cells, which will not be further discussed here, are IGF, Ang-1, sphingosine-1-
phosphate, fluid shear stress, estrogen, reactive oxygen species and 
corticosteroids 47. 
 
 
1.2.2. The Raf-MEK-ERK Pathway 
Another signalling pathway of critical importance for the angiogenic process is the 
Raf-MEK-ERK pathway also referred to as the mitogen activated protein kinase 
(MAPK) pathway. This pathway has repeatedly been shown to protect cells from 
apoptosis 56,57 and be essential for proliferation and cell cycle progression 58,59. 
Moreover, this pathway has also been demonstrated to be involved in extracellular 
matrix degradation, endothelial cell migration as well as differentiation 25.  
 
Raf is a serine/threonine protein kinase (also called the mitogen activated protein 
kinase kinase kinase, MAPKKK) and three Raf isoforms exist in higher eucaryots, 
namely Raf-1 or c-Raf, A-Raf and B-Raf. They all share three domains: 1) CR1, 
which has a binding site for Ras, 2) CR2, which renders the kinase inactive when 
phosphorylated on a serine residue and 3) CR3, which when phosphorylated on a 
serine and two tyrosine residues positively controls Raf activity 58,59. Although all Raf 
isoforms share this homology, they differ in action. Maximal activation of Raf-1 and 
A-Raf requires both Ras and Src activity whereas B-Raf only needs Src. Moreover, it 
has been shown that VEGF and FGF induces robust activation of Raf-1 while B-Raf 
was only weakly activated by FGF and not activated at all by VEGF in endothelial 
cells 56. It has been shown in NIH 3T3 cells that A-Raf promotes cell cycle 
progression, whereas B-Raf and Raf-1 caused cell cycle arrest. Intriguingly, in 
hemotopoetic cells the activation of Raf-1 and A-Raf induced cell proliferation while 
B-Raf activity resulted in apoptosis 59. Furthermore, the tissue distribution of the Raf 
isoforms also differ. Raf-1 is expressed ubiquitously while the strongest A-Raf 
expression is found in urogenital tissues and B-Raf predominates in neuronal tissues. 
Interestingly, B-Raf knockout mice showed severe defects in vascular endothelial cell 
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survival and differentiation leading to embryonic death and A-Raf knock-out mice 
died shortly after birth with gastrointestinal and neurological defects. Raf-1 knock-out 
mice however, died embryonically and had defects in the development of skin, lung 
and placenta 59.  
 
Upon growth factor receptor activation the adaptor proteins Shc and Grb2 pull the 
GDP/GTP exchanger protein Sos (son of sevenless) towards the cell membrane 
where it activates Ras 58-60. This causes a conformational change of Ras which 
reveals a high affinity binding site for Raf that results in the translocation of Raf to the 
cell membrane. This in turn enables other proteins such as Rac1, p21 activated 
kinase (PAK), Src kinase and protein kinase C (PKC) to thereby activate Raf 58-61. It 
has been demonstrated that VEGF induced activation of the Raf-MEK-ERK pathway 
occurs mainly through PKC following its own activation by phospholipase C γ (PLCγ), 
and to a lesser extent through the Ras dependent pathway 62. Furthermore, this route 
of Raf-MEK-ERK pathway activation is the strongest inducer of proliferation upon 
VEGF 25. In either way, by phosphorylation of two serine residues Raf activates the 
MAPK kinases (MAPKK) MEK 1 and MEK 2. Following MEK activation, Raf activity is 
abrogated by phosphorylation by protein kinase A (PKA) 58,59. There are some 
studies reporting an inactivation of Raf caused by Akt 63,64, whereas others claim 
PKA is the main inhibitor of Raf 58,59. Raf inhibition by Akt primarily seems to depend 
on the cell type and the differentiation stage of the cell 59,63,64. 
 
For MEK 1 and 2, the extracellular signal regulated kinase ERK 1/2 is the only target 
and it activates ERK1/2 (also called p42 and p44) by phosphorylation of a tyrosine 
and a threonine residue 65. ERK transduces the signal initiated by Raf by 
phosphorylation of several nuclear transcription factors such as Ets-1, c-Jun and 
c-Myc. In addition, it indirectly activates the transcription factor CREB. Activation of 
the above mentioned proteins lead to transcription of genes which positively regulate 
cell cycle progression and cell survival. Furthermore, by phosphorylating IKK, ERK 
indirectly activates NFκB and can so induce expression of genes important for 
immune responses, proliferation, prevention of apoptosis and angiogenesis. Mainly 
though, Raf activation can also lead to NFκB activation independently of ERK, by 
activation of MEKK 1 59. It has been demonstrated by Cheresh et al. that VEGF was 
able to activate Raf-1 through Src and this rescued endothelial cells from stress 
 21 
mediated apoptosis (intrinsic pathway) while bFGF enhanced Raf-1 activity by 
phosphorylation of PAK thereby preventing endothelial cells from undergoing 
receptor mediated apoptosis (extrinsic pathway) 56.  
 
Besides affecting proliferation and cell survival, the Raf-MEK-ERK pathway is also a 
mediator of cell migration upon VEGF receptor and integrin activation. In this context 
it is activated by FAK which regulates the assembly of focal adhesions and the 
organization of actin. In addition, Raf is activated by the small GTPase Rac which 
drives actin polymerization and formation of lamellopodia that are also important for 
cell migration 25. Another important step of angiogenesis, where the Raf- MEK-ERK 
pathway also seems to be highly involved is extracellular matrix degradation. Upon 
FGF or VEGF stimulation this pathway is activated by the Grb2/Sos/Ras complex 
resulting in the expression of Ets-1 and matrix metalloproteinases 25.  
 
The last steps of the angiogenic process which involves endothelial cell 
differentiation also includes the Raf-MEK-ERK pathway. Not much is known about 
the precise signalling mechanisms regulating this process, but FGF and VEGF seem 
to activate Raf either through PI3-Kinase or PLC respectively. Thus, the Raf-MEK-
ERK pathway is involved in almost all steps of angiogenesis and can be activated in 
many different ways by several different stimuli (for a schematic picture of the Raf-
MEK-ERK pathway in angiogenesis, see fig. 1.4). 
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Fig. 1.4 The Raf-MEK-ERK pathway and its effects on angiogenesis. 
The Raf-MEK-ERK pathway is responsible for many important features in the 
angiogenic process, such as cell migration, survival, differentiation, proliferation and 
degradation of the extracellular matrix (ECM) by activation of several transcription 
factors such as Ets-1, c-Myc, NFkB, CREB and c-Jun. Most of the effects are 
mediated through Raf dependent activation of MEK and ERK but NFkB activation 
has also been shown to be mediated by Raf dependent MEKK 1 activation. Several 
kinases have been shown to activate Raf and the activation of these upstream 
regulators seem to be dependent on the stimulus given. 
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1.3. THE SRC-HOMOLOGY 2 DOMAIN CONTAINING TYROSINE 
PHOSPHATASE 2 
Cellular responses to the environment are mediated by intracellular signalling 
pathways. They can be initiated by growth factors, cytokines, hormones, cell 
adhesion molecules and extracellular matrix components. The different transduction 
pathways monitor several fundamental cellular activities like proliferation, migration, 
differentiation and survival. These processes are in turn dependent on and regulated 
by protein phosphorylation and dephosphorylation carried out by protein kinases and 
protein phosphatases respectively. Protein phosphorylation or dephosphorylation is 
responsible for protein activation, inhibition and direct interaction between proteins, 
which are very important for transducing the original message and dysregulation of 
the signalling pathways causes malfunctioning of the cells and may eventually lead to 
disease. Many extracellular stimuli, which are important for cellular homeostasis, 
activate a signal pathway by inducing phosphorylation of tyrosine residues on their 
receptors and the activities of several of the intracellular proteins transmitting the 
signal further also depend on tyrosine phosphorylation. Protein tyrosine kinases 
(PTK) and protein tyrosine phosphatases (PTP) thus play critical roles in the control 
of cellular behaviour.  Until a few years ago it was believed that tyrosine 
phosphorylations were mainly regulated by protein tyrosine kinases but there are 
now many studies showing that protein tyrosine phosphatases are equally important. 
However, the knowledge about their signalling mechanisms is not as well profound 
as with tyrosine kinases. The PTP superfamily consists of three families: classical 
PTPs, which dephosphorylate tyrosine residues, dual specificity phosphatases 
dephosphorylating serines, threonines and tyrosine residues within the same protein 
substrate and atypical PTPs lacking activity against conventional PTP substrates. 
The classical PTPs consists of transmembrane PTPs and non-transmembrane 
PTPs 66-68. In vertebrates, two non transmembrane Src homology domain containing 
tyrosine phosphatases exist, namely Src homology 2 domain containing tyrosine 
phosphatase 1 and – 2 (SHP-1 and SHP-2 respectively). This study concentrates on 
SHP-2. 
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1.3.1. The biochemistry of SHP-2 
Mammalian SHP-2 (also called SH-PTP2, SH-PTP3, PTP2C, PTP1D or Syp) was 
first discovered and cloned in 1992 by Neel et al 69 and has homologues in both 
Drosophila (Corkscrew, shortened Csw) and C. elegans (Ptp2). SHP-2 is an 
ubiquitously expressed protein with the highest levels being expressed in heart, brain 
and skeletal muscle 70. As stated by the name, SHP-2 contains two tandem Src 
homology 2 (SH2) domains at the N-terminus of about 100 amino acids each (N-SH2 
and C-SH2). The SH2 domains mediate the binding of SHP-2 to phosphorylated 
tyrosine residues on other molecules and thus control the specific protein-protein 
interaction between SHP-2 and its substrates 71,72. The SH2 domains also regulate 
the phosphatase activity. It has been shown that binding of a phosphotyrosyl peptide 
to the N-SH2 domain stimulates activation of the phosphatase domain (PTP), which 
is situated at the C-terminus and exhibits a low basal activity. In addition, 
biphosphorylated ligands (ligands that contain two phosphorylated tyrosine residues) 
that bind both SH2 domains further stimulate catalysis 71,73. Interestingly enough, 
deletion of the N-SH2 part of the protein, but not the C-SH2, also leads to an 
enhanced activation of SHP-2 implying that the N-SH2 domain is critical for 
inactivation of the phosphatase. The crystal structure of SHP-2 revealed that the 
N-SH2 domain is inserted into the catalytic cleft of the phosphatase domain in the 
basal state and so sterically hinders phosphatase activity. At the same time, the 
p-Tyr binding pocket on the N-SH2 domain is hidden away from other substrates. 
There are two suggested mechanisms for SHP-2 activation (for a schematic picture 
see Fig. 1.5). In the first suggested mechanism two tyrosine residues (Y542 and 
Y580) in the C-tail of SHP-2 are phosphorylated and can therefore bind to the N-SH2 
and C-SH2 domains respectively. This binding leads to the exposure of the catalytic 
cleft of the PTP domain now able to exert its phosphatase activity. The tyrosine 
residue at position 542 has been shown to be the major in vivo phosphorylation site 
on SHP-2 74. In the second way of activation, which is supported by both crystal 
structure and enzymological studies 73,  the C-SH2 domain is left open (because only 
the N-SH2 domain is captured by the phosphatase domain) and can freely bind 
tyrosine phosphorylated ligands. Binding of a ligand with two p-Tyr sites to the C-SH2 
results in a local increase of the ligand concentration which is enough for the 
engaged N-SH2 domain to overcome the allosteric inhibition and bind the second 
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p-Tyr site on the substrate, thus rendering the protein active. SHP-2 ligands or 
substrates are tyrosine phosphorylated receptors or tyrosine phosphorylated adaptor 
molecules and it is believed that by either binding to receptors or other adaptor 
proteins, the SHP-2 is translocated from the cytosol to the plasma membrane where 
it exerts its action. 
 
The closest homologue to SHP-2 is the Src homology 2 domain containing tyrosine 
phosphatase 1 (SHP-1), which in contrast to SHP-2 is mainly expressed in 
hematopoetic cells. Nevertheless, both proteins share extremely high sequence 
identity. The SH-2 domains at the N-terminus of both proteins have 65% and 52% 
similarity respectively and the catalytic domains are to 60% identical 75. Moreover, 
the tertiary structures of the catalytic domains are almost superimposable, which 
makes it very complicated to develop selective inhibitors targeting the PTP domains. 
Fig. 1.5 Mechanisms of SHP-2 activation  
Two mechanisms of SHP-2 activation have been shown so far. The phosphatase is 
kept inactive by steric blockage of the PTP domain by the N-SH2 domain. Upon SH2 
domain binding to phosphorylated tyrosine residues on receptors or adaptor 
molecules the catalytic cleft in the PTP domain is left open and can so 
dephosphorylate tyrosine phosphorylated residues on other molecules (left 
mechanism). This way of activation is supported by enzymological and crystal 
structure studies. In the other suggested mechanism of SHP-2 activation the two 
tyrosine residues (Y542 and Y580) in the C-tail of SHP-2 are phosphorylated and 
therefore bind to both SH2 domains. This binding exposes the catalytic cleft of the 
PTP domain now able to exert its phosphatase activity (right mechanism). 
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1.3.2. SHP-2 and disease 
One of the best defined diseases where SHP-2 plays an outstanding role is the 
developmental disorder Noonans syndrome (NS) first described by two pediatric 
cardiologists Jacqueline Noonan and Dorothy Ehmke. NS is an autosomal dominant 
disorder defined by short stature, facial dysmorphism, skeletal anomalies and 
cardiovascular abnormalities such as congenital heart disease 76,77. The prevalence 
of this disorder is estimated between 1:1000 and 1:2500 live births, although disease 
incidence seems to be higher than prevalence, since fetal loss has been 
documented. Approximately 50% of the NS cases are caused by germline missense 
mutations situated at or close to the interface between the exons coding for N-SH-2 
and PTP domains of SHP-2 76. This suggests that the inhibitory N-terminal SH-2 
domain interaction with the PTP domain is destabilized resulting in a gain of function 
of SHP-2 (Fig. 1.6) 76. This model is supported by data obtained from NS-causative 
SHP-2 mutants, where an increased basal phosphatase activity was detected. 
Furthermore, functional studies on these mutants in vitro under basal conditions or 
upon EGF stimulation show that the destabilization of the inactive form of SHP-2, 
thus favouring the shift in equilibrium towards the active state, results in a prolonged 
ligand-dependent activation of ERK-2. Moreover, the binding of SHP-2 to Grb-2 
associated binder-1 (Gab-1) was increased 77. Mice with a NS-causative mutation 
(Ptpn11D61G/ D61G) in the gene for SHP-2, Ptpn11, die in utero of extensive edema and 
bleeding. Ptpn11D61G/+ embryonic mouse fibroblasts show features which resembles 
those observed in NS and exhibit characteristics indicating a myeloproliferative 
disease. An enhanced SHP-2 activity was also observed in this mouse model 76. 
 
Patients with NS have an increased incidence of different hematologic abnormalities 
such as transient monocytosis, thrombocytopenia and juvenile myelomonocytic 
leukaemia (JMML). The latter is characterized by excessive proliferation of myeloid 
progenitor cells which are hypersensitive to granulocyte macrophage colony 
stimulating factor (GM-CSF) due to defective Ras inhibition. 20-25% of the cases are 
due to somatic SHP-2 mutations 71,76 and some of these mutations occur at the same 
spots as mutations in NS. Interestingly, JMML and NS mutations often result in the 
incorporation of different amino acids at these positions suggesting that different 
levels of SHP-2 activity determine whether to cause NS or leukemia 71. This finding 
raised the question if mutations in Ptpn11 would have a significant impact on 
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cancers. Mutational analyses of several different tumours revealed that Ptpn11 
mutations occur at low frequency in some human cancers 76. Further, somatic Ptpn11 
mutations have been detected in children and adolescents with acute lymphoblastic 
leukaemia (ALL) 76 and an increased expression and thus activity of SHP-2 has been 
found in neutrophils from patients with severe congenital neutropenia (Kostmann´s 
syndrome) indicating that SHP-2 also is important for cell differentiation 78. 
 
 
Fig. 1.6 Mutation in SHP-2 responsible for Noonans syndrome 
Whereas the N-SH2 domain of SHP-2 sterically hinders the catalytic activity of the 
PTP domain in normal individuals, missense mutations situated at or close to the 
interface between the exons coding for N-SH-2 and PTP domains of SHP-2 results in 
a gain of function of SHP-2 in 50% of the patients diagnosed with Noonans 
syndrome. 
 
Another developmental disorder related to mutations in Ptpn11 is the LEOPARD 
syndrome (LS), which, likewise to NS, also is an autosomal dominant condition. It is 
characterized by some of the features seen in NS, such as congenital heart disease, 
short stature and facial dysmorphism, but also by café-au-lait spots, abnormal 
genitalia in male and deafness to mention a few. Since the two diseases show similar 
characteristics and because the missense mutations in LEOPARD syndrome are 
situated in the exon encoding the phosphatase domain of SHP-2, the mutations in LS 
are so predicted to also result in a gain of function of SHP-2 79. Recent data however, 
show that LS is characterized by a decreased SHP-2 activity 80. How these clinically 
similar syndromes can result from the opposing effects of these SHP-2 mutants 
remains to be clarified. 
 
SHP-2 has also been shown to be involved in both insulin dependent- (IDDM) and 
non insulin dependent (NIDDM) diabetes mellitus 70,81.  In streptozotocin-treated rats, 
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which are insulin deficient resembling IDDM, levels of SHP-2 protein in fat and liver 
tissue were decreased 81. Transgenic mice expressing a dominant negative mutant 
SHP-2 were found to be insulin resistant and exhibited an impaired insulin signalling, 
such as phosphorylation and thus activation of the insulin receptor substrate 1 
(IRS-1), PI3-K and Akt 82. Several studies of the role of SHP-2 in insulin signalling 
exist 83-86 and it has been shown that SHP-2 associates with IRS-1 upon insulin 
stimulation. Further, it has been demonstrated in cells overexpressing the insulin 
receptors that SHP-2 seems to be important for the insulin dependent MAPK- and 
PI3-Kinase activity 85,86. 
 
 
1.3.3. SHP-2 and growth factor signalling 
SHP-2 has been implicated in a variety of different signalling pathways initiated by 
several different growth factors, such as PDGF, EGF, IGF, FGF and cytokines such 
as IL-1-3, IL-5-6, GM-CSF, erythropoietin (EPO) as well as interferon and insulin. 
SHP-2 has been demonstrated to be involved in the Ras-Raf-MEK-ERK, PI3-Kinase, 
Jak-Stat and NFκB pathways. Another feature of SHP-2 is its dual role in signalling; 
although most of its effects are tyrosine phosphatase dependent, SHP-2 can 
probably also function as an adaptor molecule due to its SH2-domains and it has 
been shown to interact with several signalling intermediates such as Grb2, FRS-2, 
Jak 2, the p85 subunit of the PI3-Kinase, IRS-1 and Gab-1 and -2 71,72 as well as 
directly with receptors such as the PDGFR 87, EGFR and the VEGFR 88,89. In 
addition, SHP-2 has also been found to both positively and negatively enhance 
cellular signalling. The exact mechanism of this involvement differs somewhat 
depending on the cell type and stimulus. While it has been shown that SHP-2 
negatively regulates the Jak-Stat pathway, it seems to positively influence the Raf-
MEK-ERK and PI3-Kinase pathways 71,72, which are probably the most investigated 
pathways in the context of SHP-2. Although numerous studies showing a positive 
role for SHP-2 in these pathways exist, the exact mechanism of how SHP-2 activates 
these pathways remains to be elucidated. SHP-2 was shown to dephosphorylate the 
PDGFR on position Y771, which is the binding site of the GTPase activating protein 
RasGAP 90. This suggests a limited Ras activation in the absence of SHP-2, thus 
coupling the phosphatase to Ras-Raf-MEK-ERK signalling upon PDGF stimulus.  
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However, this model cannot account for the entire extent of SHP-2 dependent ERK 
activation, since studies with overexpression of the Grb2 associated binder-1 (Gab-1) 
resulted in an increased association of Gab-1 to SHP-2 as well as enhanced ERK 
activation upon PDGF stimulation 91. A study using a Gab-1/SHP-2 fusion protein 
suggested that SHP-2 mediates its positive effects on ERK signalling through 
activation of Src and that Gab-1 is necessary for targeting SHP-2 to the cell 
membrane and thus to the vicinity of its targets 92. Furthermore, SHP-2 has also been 
suggested to activate the Ras-Raf-MEK-ERK signalling pathway by preventing 
recruitment of the negative Src regulator Csk 93. Another potential SHP-2 target is the 
Sprouty protein, initially found to negatively regulate FGF signalling in Drosophila 71. 
An additional target for SHP-2 in FGF dependent cell signalling is the FGF receptor 
substrate 2 (FRS2). Upon FGF stimulation FRS2 associates with SHP-2 which then 
becomes phosphorylated and binds Grb2. A failure of forming this protein complex 
resulted in a weak and transient MAPK activation in embryonic kidney cells 94 and 
myoblasts 95. 
 
SHP-2 has also been shown to be important for cell survival by regulating the 
PI3-Kinase/Akt pathway 96,97. One study indicates that SHP-2 controls activation of 
PI3-Kinase by promoting the association of the docking protein Cbl, which is 
phosphorylated by Src, and the p85 subunit of PI3-Kinase 96. Furthermore, SHP-2 
has been shown to directly associate with the p85 subunit of PI3-Kinase leading to its 
activation after EGF and IGF stimulation in glioblastoma and mouse fibroblast 
cells 97,98. Intriguingly, upon EGF stimulation in fibroblasts, SHP-2 has been 
demonstrated to both positively 98 and negatively 99 regulate PI3-Kinase activity. 
Furthermore, it was shown that the EGF dependent association between Gab-1 and 
PI3-Kinase was enhanced in SHP-2 mutant fibroblasts suggesting that SHP-2 
negatively regulates PI3-Kinase activity by dephosphorylating p85 binding sites on 
Gab-1 99. SHP-2 binding to Gab-1 upon EGF stimulation linking it to PI3-kinase has 
also been shown to mediate NFκB activation 100. However, the exact mechanism of 
SHP-2 regulation of PI3-Kinase remains to be investigated. 
 
SHP-2 has also been demonstrated to regulate signalling initiated by tyrosine kinase 
receptors in vivo, as primary cells from SHP-2 mutant embryos showed a prolonged 
MAP Kinase activity upon PDGF stimulation whereas aFGF and bFGF stimulation of 
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these cells resulted in a decreased and transient MAP Kinase activation in 
comparison to wild type cells 101. In addition, cells from Shp-2 -/-/wild type chimeric 
mice showed diminished EGF-R signalling, such as reduced activation of PI3-Kinase 
and ERK 1. Apart from exhibiting defects in the formation of mesoderm during 
development, the phenotype of the Shp-2 -/-/wild type chimeric animals showed eye 
and skin abnormalities as well as immature lung development, which indicates an 
impairment in EGF signalling 102. 
 
 
Fig. 1.7 Growth factor dependent SHP-2 signalling 
 SHP-2 has been shown to take part in signalling initiated by several different factors. 
In most cases SHP-2 positively regulates PI3-Kinase and the Raf-MEK-ERK 
pathways, whereas it exhibits a negative role in the Jak-Stat pathway. However, 
SHP-2 has also been found to negatively regulate PI3-Kinase activity. The path and 
way of regulation chosen seem to depend on the stimulus and the cell type. The 
direct target for SHP-2 remains to be fully elucidated. 
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1.3.4. SHP-2 and endothelial physiology 
In endothelial cells, SHP-2 has been found to interact with adhesion molecules such 
as VE-Cadherin and platelet endothelial cell adhesion molecule (PECAM). It has 
been found to be associated with VE-Cadherin in quiescent endothelial cells and to 
dissociate from the Cadherin complex upon thrombin stimulation 103 and shear 
stress 104. Furthermore, it has been shown that association of SHP-2 to PECAM is 
important for dephosphorylation of β-catenin, a protein tightly bound to both 
VE-Cadherin and PECAM, since cells lacking PECAM-1 showed a sustained 
phosphorylation of β-catenin. This was conjoined with an increase in cell 
permeability 105. Thus, these findings suggest that SHP-2 has a role in cell-cell 
junction assembly and that dissociation of SHP-2 from these adhesion molecules 
upon stimulation with a vasoactive substance or shear stress promotes endothelial 
permeability. In addition, SHP-2 has been shown to bind to PECAM-1 and thereupon 
become active in confluent HUVEC, whereas this association is decreased in 
migrating endothelial cells. According to these results it is suggested that PECAM 
directs SHP-2 in influencing proteins important for maintaining a confluent cell layer 
106. In contrast, the observation that wound-induced migration stimulates PECAM-1 
tyrosine phosphorylation and SHP-2 association leads to the assumption that SHP-2 
may instead promote cell motility 107. A positive role for SHP-2 in endothelial cell 
migration is supported by another study showing a defective cell migration towards 
PDGF when SHP-2 is unable to associate to the PDGFR-β. Endothelial cells 
expressing a mutant PDGFR lacking the binding site for SHP-2 not only exhibit a 
reduced cell motility but also show a diminished activation of the focal adhesion 
kinase (FAK) 108, which regulates the formation of focal adhesions important for 
cellular migration.  
 
Endothelial SHP-2 also seems to be involved in the inflammatory response, as it has 
been shown to be important for proper intercellular adhesion molecule 1 (ICAM-1) 
signalling and thus neutrophil migration along the endothelium 109. In addition, SHP-2 
is probably important for E-Selectin transmembrane signalling in the activated 
endothelial cell at sites of inflammation 110.  
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In spite of these insights, to date, the data about the different signalling pathways 
influenced by SHP-2 in endothelial cells are limited. In addition, the functional 
consequences of SHP-2 signalling remain to be investigated.  
 
 
1.4. A NOVEL STRATEGY OF INHIBITING SHP-2 
1.4.1. Posttranscriptional gene silencing 
Posttranscriptional gene silencing (PTGS) defines a mechanism that serves to 
protect the genome from foreign DNA or RNA by sequence specific destruction of the 
nucleic acids. PTGS has been shown to play a critical role in normal cellular 
functions 111 and it appears to be a natural defence mechanism against viruses and 
transposable elements 112,113. It was first discovered in plants into which a transgene 
that was supposed to enhance the expression of the product encoded by the 
transgene was introduced, but instead led to the suppression of itself and of a 
homologous endogenous gene 114. Thus, this process can be induced by the 
introduction of exogenous nucleic acids which target cellular mRNA homologous to 
its sequence for cleavage, thereby silencing endogenous genes specifically 115. 
Antisense oligonucleotides (AS-ODN) and short interfering RNAs (siRNA) are 
examples of exogenous nucleic acids that switch on PTGS. However, there are other 
molecules that trigger specific mRNA cleavage such as ribozymes and which are 
also used for experimental purposes 115,116. 
 
Ribozymes, like the hammerhead ribozyme, are RNA enzymes that can be used for 
gene knock-down. They consist of a catalytic domain flanked by sequences which 
are complementary to the target mRNA enabling selective binding. The target mRNA 
is cleaved directly by the intrinsic activity of the ribozyme (Fig. 1.8). However, the 
RNA backbone makes these molecules susceptible for degradation from RNases 
and thus biological unstable in vivo. Deoxyribozymes, which are catalytic DNAs, can 
also be applied for selective gene silencing. They bind to their target RNA and 
directly cleave it in the same way as the ribozymes do. In contrast to the ribozymes, 
no natural occurring deoxyribozyme is known to exist and they exhibit a greater 
biological stability due to their DNA backbone 117,118.  
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Antisense oligonucleotides (AS-ODN) consist of approximately 15-20 
desoxynucleotides and bind to the pre-mRNAs or the mRNAs homologous to its 
sequence 116. The AS-ODN can then either occupy critical sites of the mRNA thereby 
disturbing translation or target the mRNA for degradation 113,116. By constructing 
AS-ODNs that are targeted to the 5´terminus of the mRNA, the ribosome is blocked 
by steric hindrance and translation can not be completed 116,117. Most widely used is 
the mechansim of RNase H cleavage, which is induced by AS-ODNs that are 
negatively charged (Fig. 1.8). RNase H hydrolyses RNA strands when bound to a 
DNA strand and therefore causes the degradation of mRNA 116,117. Since naked DNA 
is rapidly degraded by exo- and endonucleases in the cell, the AS-ODN can be 
modified in different ways to increase its stability. The most common protection is the 
replacement of one of the non bridging oxygen atoms in the phosphate group with a 
sulfur group, giving a so called phosphorothioate oligonucleotide 115,116,118. This 
modification gives the AS-ODN a half-life in human serum of about 9-10 hours 
compared to approximately 1 hour for unmodified AS-ODN. In addition, these 
molecules are negatively charged and therefore water soluble and activate RNase H. 
A disadvantage with these molecules is that they exhibit a slightly reduced affinity 
towards complementary RNAs, but instead a greater specificity of hybridization 
compared to unmodified AS-ODN. Another disadvantage of phosphorothioate 
AS-ODN is the ability to bind to certain proteins, such as heparin-binding proteins. 
However, this shortcoming was proven to be of advantage in in vivo situations, where 
AS-ODNs bound plasma proteins which protected them from filtration and increased 
their serum half-life 116. 
 
The use of short interfering RNAs (siRNA) to silence protein expression is expanding 
rapidly. This technique takes advantage of the process of RNA interference (RNAi), 
which was first discovered in Caenorhabditis elegans, Drosphila and plants 119 but 
has also been observed in different vertebrate systems 120 such as in early mice 
embryos, zebrafish and Xenopus 119. Naturally occurring RNAi is triggered by dsRNA 
that targets single-stranded RNA homologous in sequence to the dsRNA for 
degradation 119,120.  
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It has been shown that dsRNA is a potent inducer of nonspecific gene silencing in 
mammalian cells due to activation of the interferon response. These nonspecific 
responses have for quite a time disturbed the detection of RNAi in somatic 
mammalian cells 119,120. A breakthrough came when the nonspecific gene silencing of 
dsRNA in mammalian cells was shown to be length-dependent 119 and that this can 
be overcome by introduction of short interfering RNAs with less than 30 nucleotides, 
that can be either expressed endogenously (short hairpin RNA) or delivered 
exogenously 117,120. Endogenously expressed hairpin RNA (shRNA) is cut into shorter 
RNAs, by the cytosolic RNAse III enzyme Dicer 120. The short interfering RNAs 
(siRNA) assemble with the RNA-induced silencing complex (RISC) and target mRNA 
homologuous in sequence for degradation by RISC 120. Due to its helicase activity, 
RISC separates the two mRNA strands, thereby enabling the siRNA to bind to the 
target mRNA. RISC also exhibits an endonuclease activity which then hydrolyses the 
mRNA at the site of siRNA binding 121 (Fig. 1.8). Although reported to be the most 
potent antisense technology discovered so far, a major disadvantage with this 
technique is the off-target effects, i.e the non specific silencing of other proteins 122. 
This can partly be overcome by lowering the siRNA concentration, however at the 
expense of efficiency.  
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Fig. 1.8 Strategies to suppress protein translation 
Short interfering RNA (siRNA) can be produced by either cleavage by Dicer from 
longer dsRNA (A, top left), chemical synthesis (A, top middle) or transcription from a 
vector containing the target sequence (A, top right). In all cases, siRNA assembles 
with RISC and directs mRNA cleavage. AS-ODN binds to mRNA homologous in 
sequence and can either prevent translation by blocking the ribosome or induce 
mRNA cleavage by a RNase H dependent mechanism (B, bottom right). Ribozymes 
and Deoxyribozymes also bind mRNA homologous in sequence but exhibit an 
intrinsic catalytic activity and so silence the gene product (C, bottom left). 
 
 
1.4.2. Magnetofection- a highly efficient tool for transfection of 
endothelial cells 
The challenge for all antisense based technologies is the efficient delivery of these 
molecules into cells, tissues or organs as the negative charge of RNA and DNA 
molecules limits the cellular uptake. A new method of introducing gene vectors into 
cells is the so called magnetofection method, invented by Plank and colleagues at 
the Institute of Experimental Oncology at the Technical University of Munich, 
Germany, where magnetic nanoparticles associated with vector DNA are transfected 
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into cells by the influence of an external magnetic field 123 (Fig. 1.9). This technique 
has been shown to enhance the efficiency of both viral or non viral vectors up to 
several thousand times 124. 
 
Magnet
Culture plate
AS-ODN coupled to 
magnetic beads
 
Fig. 1.9 The method of magnetofection 
Magnetic nanoparticles coated with Polyethylenimine bind to DNA due to their 
positive charge. This complex is applied to and transfected into the cells by a short 
time (15 minutes) influence of an external magnetic field. 
 
There are several advantages of using this transfection method. When performing 
transfection in vitro this method provides a quick and easy way to introduce DNA into 
cells. The incubation time of the DNA-nanoparticle complexes with the cells is greatly 
reduced (from standard 2-4 hours to 15 minutes) with a vast increase in vector 
concentration at the cell surface as the consequence. This in turn means that the 
vector dose needed for yielding a satisfying transfection level also can be 
reduced 124-126. Further, since these magnetic particles do not rely on receptors or 
other cell membrane bound proteins for cell uptake, it is possible to transfect cells 
that normally are non permissive 124. Importantly, the magnetofection method in 
combination with a standard lipid transfection reagent has been shown to 
successfully deliver AS-ODN to primary human umbilical vein endothelial cells 
(HUVEC), which are known to be transfected with difficulties, with transfection 
efficiencies of over 80%. Furthermore, this was associated with a low cellular 
toxicity 125. 
 37 
 
The possibility of  directing the transfection towards a specific area using an external 
magnetic field gives this approach many advantages for in vivo use 124,125,127. 
Combining drugs with nanoparticles would reduce systemic side effects and yield a 
higher concentration of the drug at the target site 127. Administration of a lower 
amount of the drug would also probably be sufficient (as for the in vitro situation), 
further reducing systemic side effects. Experiments of delivering anti tumour agents 
in this way have already been performed successfully in humans 128. 
 
1.5. OBJECTIVES OF THIS STUDY 
SHP-2 has been implicated in several different signalling pathways initiated by a 
variety of growth factors and cytokines. Pathways shown to be influenced by SHP-2 
are the Ras-Raf-MEK-ERK, PI3-Kinase, Jak-Stat and NFκB signalling cascades. 
Although numerous studies showing a positive role for SHP-2 in these pathways 
exist, the exact mechanism of how SHP-2 activates these signalling cascades 
remains to be elucidated. Furthermore, apart from its phosphatase activity, SHP-2 
can probably also function as an adaptor molecule due to its SH2-domains and has 
been shown to interact with signalling intermediates 71,72 as well as directly associate 
with receptors 87,88,89. Apart from this, SHP-2 has also been shown to influence 
cellular signalling both positively and negatively depending on the cell type and 
stimulus 71,72.  Most studies involving SHP-2 so far have been performed in mouse 
fibroblasts or other equivalent cell lines. Limited studies of SHP-2 signalling in 
primary human endothelial cells exist and the actual functional effects of SHP-2 in 
endothelial signalling remain to be investigated. In addition, the possible role of 
SHP-2 in the angiogenic process is so far unknown. Therefore, this study is aiming at 
investigating the following questions: 
 
1.5.1. SHP-2 and angiogenesis initiation 
 Is SHP-2 important for the initial steps of angiogenesis, such as growth factor 
induced proliferation? 
 Is a functional SHP-2 a prerequisite for angiogenesis initiation by preventing 
endothelial apoptosis? 
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1.5.2. SHP-2 and vessel formation 
 Is SHP-2 required throughout the angiogenic process, by affecting the 
differentiation of endothelial cells into tube like structures? 
 Is SHP-2 important for proper vessel formation, such as vessel sprouting and 
branching? 
 
1.5.3. SHP-2 and endothelial signalling  
 Do angiogenic growth factors, such as FGF, VEGF and PDGF, activate SHP-2 
in endothelial cells? 
 Does SHP-2 influence known anti-apoptotic and proliferation enhancing 
signalling pathways such as the PI3-Kinase/Akt and the Raf-MEK-ERK 
pathway in endothelial cells? 
 If so, is the effect of SHP-2 on these pathways of positive or negative manner 
upon VEGF, FGF and PDGF stimulation? 
 Which are the signalling intermediates linking SHP-2 to these pathways in 
endothelial cells? 
 
To be able to answer these questions, we chose to silence the expression of the 
SHP-2 protein by antisensedesoxynucleotides (AS-ODN) using the magnetofection 
technique. For this the following parameters had to be determined: 
 The transfection efficiency achieved by the magnetofection method of 
endothelial cells 
 Cell cytotoxicity after magnetofection of endothelial cells 
 The kinetic of  SHP-2 knock-down 
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2. MATERIALS AND METHODS 
“No amount of experimentation can ever prove me right, 
a single experiment can prove me wrong” 
˜Albert Einstein˜ 
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2.1. CHEMICALS 
Endothelial growth media was purchased from PromoCell (Heidelberg, Germany), 
new born calf serum and fetal calf serum were purchased from Biochrom (Berlin, 
Germany). Accutase was purchased from PAA (Graz, Austria). Collagenase A was 
provided by Roche (Mannheim, Germany). Collagenase I and the 
polyacrylamide:bisacrylamide solution in SDS-PAGE was from Genaxxon 
Biosciences (Biberach, Germany). Collagen G was purchased from Biochrom AG 
(Berlin, Germany). All other cell culture reagents were obtained from Sigma-Aldrich 
(Taufkirchen, Germany). Membranes used for sterilization of cell culture media and 
solutions were from MembraPure GmbH (Bodenheim, Germany). Leupeptin, 
aprotinin and pepstatin used in lysis buffers and the chemiluminescence detection kit 
for horseradish peroxidase were ordered from Applichem (Darmstadt, Germany). The 
BCA (bicinchoninic acid) protein assay reagent kit was provided by Pierce (Bonn, 
Germany). MACS separation columns and µMACS Protein G Microbeads used for 
immunoprecipitations were purchased from Miltenyi Biotec (Bergisch Gladbach, 
Germany). The Annnexin V Apoptosis detection kit 1 and growth factor reduced 
Matrigel matrix used for the capillary like sprouting and aortic ring sprouting assays 
were purchased from BD Biosciences (Heidelberg, Germany). The nitrocellulose 
membrane for the blotting of proteins in Western blots was obtained from PeqLab 
(Erlangen, Germany) and the non fat dry milk powder used in blocking buffers for 
western blots was from Saliter (Obergünzburg, Germany). The growth factor bFGF 
was purchased from Tebu-bio (Offenbach, Germany) and the SHP-2 inhibitor Ptp 
inhibitor IV was provided by Calbiochem (Darmstadt, Germany). Sodium 
pentobarbital (Narcoren) for euthanizing the mice for the aortic ring sprouting assay 
were ordered from Merial GmbH (Hallbergmoos, Germany) and the Tutofusin Voll-E 
solution used to rinse the dissected mouse aortas was obtained from Baxter 
Deutschland GmbH (Unterschleissheim, Germany). Effectene transfection kit was 
purchased from Qiagen (Hilden, Germany) and the superparamagnetic iron oxide 
nanoparticles coated with the polycation polyethylenimine (TransMAGPEI) were kindly 
provided by Chemicell (Berlin, Germany). All other chemicals were purchased from 
Sigma-Aldrich (Taufkirchen, Germany). 
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2.2. CELL CULTURE AND CELL LINES 
Media and solutions 
HUVEC growth medium (20%)   HUVEC starvation medium (1%) 
M199       M199 
+ New born calf serum (NBCS) 20%  + New born calf serum (NBCS) 1% 
+ Endothelial growth media 10%  + Penicilline/Streptamycine 1% 
+ Penicilline/Streptamycine 1%  pH 7.4 
pH 7.4       
 
HMEC growth medium (10%)   HMEC starvation medium (1%) 
M199       M199 
+ Fetal calf serum (FCS)  10%  + Fetal calf serum (FCS)  1% 
+ Endothelial growth media 10%  + Penicilline/Streptamycine 1% 
+ Penicilline/Streptamycine 1%  pH 7.4    
pH 7.4 
PAEC growth medium (10%)     
Dulbeccos´s modified Eagle´s medium (DMEM)    
+ Fetal calf serum (FCS)     10%   
+ Penicilline (10 000 U) / Streptamycine (10 mg) 1% 
+ L-Glutamine      200 nM 
pH 7.4 
 
PAEC starvation medium (1%) 
Dulbeccos´s modified Eagle´s medium (DMEM) 
+ Fetal calf serum FCS     1% 
+ Penicilline (10 000 U) / Streptamycine (10 mg) 1% 
+ L-Glutamine      200 nM 
pH 7.4 
 
Sterilization of media was performed by first filtering the solutions through a glas filter 
(C5) with a pore size of 0.45 µm followed by filtration through a second filter (Memfil 
CA) with a pore size of 0.2 µm. 
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HUVEC freezing media 
Dimethylsulfoxid (DMSO)  10% 
in new born calf serum 
 
HMEC and PAEC freezing media 
DMSO    10% 
in fetal calf serum 
 
Phosphate buffered Saline  
PBS+   PBS– 
NaCl   8 g   8 g 
KCl   0.20 g   0.20 g 
Na2HPO4  1.15 g   1.42 g 
KH2PO4  0.20 g   0.20 g 
MgCl2   0.04 g  
CaCl2   0.50      
Distilled H2O  ad 1000 ml  ad 1000 ml 
pH 7.4 
 
Collagenase A solution 
Collagenase type I (1700 U/mg)  1g 
PBS+      ad 1000 ml 
 
The solution was passed through the filter Membrex 25 CA with a pore size of 0.2 µm 
for sterilisation. 
 
2.2.1. Isolation and cultivation of human umbilical vein endothelial 
cells 
The human umbilical cords were kindly provided by the obstetrical department of the 
Ludwig Maximilians University hospital of Munich. Written and informed consent was 
obtained from all patients. To isolate human umbilical vein endothelial cells (HUVEC) 
the vein in the umbilical cord was first rinsed with warm phosphate buffered saline 
supplemented with Ca2+ (PBS+). To detach the endothelial cells from the vessel wall, 
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the umbilical cord vein was incubated with 1 mg/ml collagenase A solution in a 
humidified incubator for 10 minutes. The primary endothelial cells were then washed 
out of the vessel with HUVEC growth medium (20%). Following collection of the cells, 
they were pelleted by centrifugation at 1200 rpm (Heraeus Megafuge 1.0R from 
Kendro, Langenseldbold, Germany) for 5 minutes at room temperature and 
subsequently washed with M199 medium. Finally, the purified primary endothelial 
cells were obtained in standard culture flasks in endothelial growth medium and left 
to grow at 37 °C in a humidified incubator with 5% CO2. When reaching confluency, 
the cells were passaged and maintained in HUVEC growth medium (20%) at 37 °C 
with 5% CO2 in a humidified incubator. The primary HUVECs were used until the 
third passage only. 
 
2.2.2. Isolation and cultivation of porcine arterial endothelial cells 
Isolation of porcine arterial endothelial cells (PAEC) was performed as previously 
described by Gloe et. al 129. Briefly, fresh aortas from pig were kindly provided from 
the local slaughterhouse and kept in PBS+ until final preparation. Before dissection of 
the aorta, fat together with connective tissue was removed. The aorta was then cut 
longitudinally to expose the luminal surface followed by washing in PBS+. With the 
luminal side facing upwards, the vessels were positioned into a frame and incubated 
with a sterile collagenase A solution (1 mg/ml) for 20 min at 37 °C in a humidified 
incubator. Lastly, the endothelial cells were washed out of the vessel with culture 
medium and further cultivated in standard plastic culture dishes. The cells were 
maintained in PAEC growth medium (10%) at 37 °C with 5% CO2 in a humidified 
incubator.  
 
2.2.3. Cultivation of human microvascular endothelial cells 
Human micro vascular endothelial cells (HMEC) were provided by Ades et al 130 and 
cultured in HMEC growth medium (10%). The cells were maintained at 37 °C with 5% 
CO2 in a humidified incubator.  
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2.2.4. Passaging of cells 
Confluent cells were washed once with warm PBS- followed by incubation with 
trypsin-EDTA for approximately 2 minutes to allow the majority of the cells to detach 
from the cell culture dish. The enzymatic activity of trypsin was inhibited by 
application of the respective media containing at least 10% serum. Non attached 
cells were gently scraped off the dish with a rubber scraper and the cell suspension 
diluted in the respective media followed by seeding onto new culture dishes. 
 
2.2.5. Freezing of cells 
To be able to always keep a stock of endothelial cells, a fraction was always kept 
frozen. For this, confluent endothelial cells (HUVEC, HMEC or PAEC) were 
incubated with trypsin (1 ml) for approximately 2 minutes. The enzymatic reaction 
was inhibited by the addition of their respective freezing media (1 ml). The cells were 
then gently but quickly scraped off the cell culture dish with a rubber scraper and 
collected in cryo-vials. The cells were kept at -80 ˚C for 24 hours before final storage 
in liquid nitrogen. 
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2.3. MOLECULAR BIOLOGY 
2.3.1. AS-oligodesoxynucleotide transfer 
 
Solutions 
Transfection solution 
Table 1: Mixing scheme for the transfection solution 
Chemicals Conc. Amount / well in 
a 24 well plate 
Amount in a 
60 mm culture 
dish 
Amount in a 
100 mm culture 
dish 
Ratio 
Chemical: 
AS-ODN 
AS-ODN 1 µg/µl 0.6 µl (0.6 µg) 1 µl (1 µg) 7 µl (7 µg)  
Enhancer 
Solution 
1 mg/ml 4.8 µl 8 µl 56 µl 8 µl / µg AS-ODN 
TransMAGPEI 1 mg/ml 1.2 µl 2 µl 14 µl 2 µl / µg AS-ODN 
EC Buffer  25.4 µl 89 µl 123 µl  
Effectene 1 mg/ml 6 µl 10 µl 70 µl 10 µl / µg AS-
ODN 
Media  162 µl 890 µl 1730 µl  
Media added to 
cells before 
transfection 
 200 µl 1 ml 2 ml  
Total volume  400 µl 2 ml 4 ml  
 
HMEC growth media (10%) 
See section 2.2 
 
HMEC starvation media (1%) 
See section 2.2 
 
HUVEC growth media (20%) 
See under section 2.2 
 
Experimental procedure 
To achieve a knock-down of SHP-2 protein, phosphorothioate modified 
oligodesoxynucleotides (ODN) were transferred into endothelial cells using the 
previously described magnetofection technique 125 together with the Effectene 
transfection kit. In detail, DNA oligos were mixed with Enhancer Solution, 
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TransMAGPEI and EC buffer according to table 1. After short vortexing and incubation 
at room temperature for 2-5 minutes, Effectene was added according to table 1 and 
the solution was incubated at room temperature for another 10 minutes. HUVEC 
growth medium (20%) or HMEC growth medium (10%) were then applied to the cells 
to be transfected in the following amounts: 200 µl / well in a 24 well plate, 500 µl for a 
60 mm cell culture dish and 1 ml for a 100 mm cell culture dish. HUVEC growth 
medium (20%) or HMEC growth medium (10%) were mixed with the transfection 
solution (according to table 1) before applying the solution to the cells. For AS-ODN 
delivery into the cells, the cell culture plate was immediately put upon a 
neodymium-iron boron magnet in the humidified incubator for 15 minutes. The cells 
were then rinsed gently three times with PBS+ and left in fresh medium. For 
experiments the cells were kept in culture, in HUVEC growth medium (20%), HMEC 
growth medium (10%) or HMEC starvation medium (1%), as far as not otherwise 
stated, for 6-24 hours following transfection.  Oligonucleotide sequences designed 
according to GenBank entry number XM_293497 were as follows: SHP-2 AS-ODN: 
5´ctccgcgatgtcatgttcct 3´, Rdm ODN: 5´cccttatttactactttcgc 3´ (both from MWG 
Biotech, Ebersberg, Germany). The GC/AT ratio was 55% and 40% respectively. 
Both ODNs had phosphorothioate added to the first 4 nucleotides on the 5´end and 
to the five last nucleotides on the 3´end to protect them from degradation. 
Blast-searches through the NCBI database were done with the sequences to ensure 
no alignment with other mRNAs of mouse or human kind.
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2.3.2. Assessment of transfer efficiency 
Solutions 
 
Propidium iodide staining solution 
Propidium iodide   0.6 mg 
in 50 ml HEPES buffer 
 
Formaldehyde solution 
Formaldehyde   2% 
in HEPES 
 
Sodium citrate solution 
Sodium citrate (NaCi)  15 mM 
KCl     135 mM 
 
Other reagents 
Cy-3 labelled Rdm ODN  0.6 µg / well in a 24 well plate format 
 
Experimental procedure 
HMEC were transfected using the magnetofection method as described in section 
2.3.1. ODN uptake into endothelial cells 4 hours post transfection  with a Cy-3 
(carbocyanin) labelled ODN was quantified by FACScan flow cytometer (BD 
Biosciences, Heidelberg, Germany) after enzymatic removal of the cells with 
trypsin-EDTA from the culture dish. The cells were washed with PBS+ followed by 
fixation in 2% formaldehyde for 10 minutes at room temperature. Photos of cells 
transfected with Cy-3 labelled ODN were taken 4, 16 and 24 hours post transfection 
with an invert laser scanning microscope (LSM 410, Zeiss, Jena, Germany) using a 
570 nm longpass emission filter and exciting at 543 nm. Cytotoxicity was assessed 
24 hours following AS-ODN transfection by propidium iodide staining. Cells were 
detached from the cell culture dish nonenzymatically with sodium citrate, incubated 
with the propidium iodide solution for 20 minutes in the dark followed by washing 
three times with PBS+. Finally, the cells were fixated in a 2% formalin solution. Cells 
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staining positive for propidium iodide, as analysed by flow cytometry, were assumed 
to be non viable.  
 
To evaluate the efficiency of SHP-2 AS-ODN to degrade SHP-2 mRNA and so detain 
SHP-2 protein expression in the experiments in this study, the SHP-2 protein level 
was detected using the western blotting technique (described in detail in 
section 2.4.1) 6, 24 and 48 hours post AS-ODN transfection.  As a control for loading 
the SDS-PAGE with equal amounts of protein, the membranes were incubated with 
an α-Actin antibody after stripping (see section 2.4.1). The protein bands were 
detected using a bioluminescence detection system attached to a digital camera 
(Sequoia, Hamamatsu, Herrsching am Ammersee, Germany). The density of the 
protein bands were measured as intensity/pixels in regions of interests (ROI) with the 
software WASABI version 5.1 to reveal the extent of inhibition of SHP-2 protein 
translation. The ratio of the SHP-2/Actin protein band was calculated to enable a 
comparison between western blots. 
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2.3.3. Cell extracts for immunoprecipitations, western blot analysis 
and SHP-2 activity measurement 
Buffers and solutions 
Lysis buffer 
KH2PO4      20 mM 
Ethylenediaminetetraacetic acid (EDTA) 1 mM   
Pefablock      1 mM    
Leupeptin      1 µM   
Pepstatin      1 µM   
NaF       50 mM  
Na407P2      40 mM 
Na3VO4      2 mM  
pH 7.3 
 
Before usage of the buffer, Triton X-100 was added to a final concentration of 1%. 
 
Lysis buffer for SHP-2 activity measurement 
Tris    20mM 
EDTA    1mM 
Pefablock    1mM 
Leupeptin   1µM 
Pepstatin   1µM 
Aprotinin   1µM 
NaF    50mM 
Na407P2   40mM 
pH 7. 35 
 
Before usage of the buffer, Triton X-100 and sodium desoxycholate (DOC) was 
added to a final concentration of 1%  and 0.5% respectively. 
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Sodium orthovanadate (Na3VO4) 200 mM 
Sodium orthovanadate is a non specific inhibitor for tyrosine phosphatases. To 
achieve maximal inhibition of protein tyrosine phosphatases, the sodium 
orthovanadate has to be activated. Depolymerisation and so activation of sodium 
metavanadate (NaVO3), converting it into Na3VO4, was achieved through the 
following procedure: 
1) NaVO3 was solved in distilled H2O to a final concentration of 200 mM and the 
pH was set to 10. Under these conditions the solution is yellow. 
2) The solution was boiled in a water bath until it was colourless 
3) The solution was left to cool down to room temperature before the pH was 
again set to 10. 
4) The steps 2 and 3 were repeated until the pH stabilized at 10 and the solution 
remained colourless independent of temperature. 
Aliquots were kept at -20 ˚C until further usage. 
 
Experimental procedure 
To obtain protein lysates the cells were washed once with PBS+ and immediately put 
on ice and lysed for 10 minutes using ice-cold lysis buffer. For cells appointed for 
SHP-2 activity measurement, the cells were lysed with SHP-2 activity lysis buffer. 
The cells were then scraped off the dish with a rubber scraper and passed repeatedly 
through a 29 g needle. The debris was removed from the lysate by centrifugation at 
10 000 g for 10 minutes and at a temperature of 4 °C. The protein concentration for 
the remaining solution was determined using BCA (bicinchoninic acid) protein assay 
reagent kit according to the manufacturer’s protocol (see section 2.3.4). The protein 
lysates were either directly analysed or kept frozen at -20 °C until further handling. 
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2.3.4. Assessment of protein concentration 
 
Materials 
BCA protein assay reagent kit 
Bovine Serum albumin solution   2 mg/ml in distilled water 
 
Experimental procedure 
The BCA (bichinconinic acid) protein assay reagent kit is based on the biuret reaction 
where Cu2+ is reduced to Cu1+ by proteins in an alkaline medium. Addition of 
bichinconinic acid leads to a purple-coloured end product which can be detected 
colometrically at 562 nm. This end product is formed by the chelation of two 
molecules of BCA with one Cu1+ and is almost linear with increasing protein 
concentrations. 10 µl of protein lysate was added to a well in a 96 well plate formate 
prior to application of 200 µl BCA solution (mixed according to the supplier´s 
protocol). Every sample was measured in triplicates with SpectraFluor (Tecan, 
Crailsheim, Germany). A dilution series with BSA was run alongside with the protein 
lysates for the establishment of a standard curve. The mixture was incubated for 30 
minutes at 37 ˚C prior to measurement at 550 nm. The protein concentration was 
calculated according to the following formula: 
 
f(x)= m x + b 
 
where x has to be dissolved to reveal the protein amount in µg and m= gradient of 
the standard curve; b= axis intercept of the standard curve and f(x)= the absorbance 
data obtained. 
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2.4. PROTEIN CHEMISTRY 
2.4.1. Western Blot analysis 
Reagents and solutions 
 
SDS-PAGE 
Separation gel (10%): 
Distilled H20       20 ml  
Tris 1.5 M pH 8.8      12.5 ml 
Sodeum dodecyl sulfate (SDS) 10%   0.5 ml 
Acrylamide/Bisacrylamide 30% / 0.8% (w/v)  16.6 ml 
Ammoniumpersulfate 10% (w/v)    0.25 ml 
TEMED       0.025 ml 
 
Stacking gel (4%):       
Distilled H2O       6 ml 
Tris 0.5 M pH 8.8      2.5 ml 
SDS 10% (w/v)      0.1 ml 
Acrylamide/Bisacrylamide 30% / 0.8% (w/v)  1.3 ml 
Ammoniumpersulfate 10% (w/v)    0.05 ml 
TEMED       0.01 ml 
 
For both gel solutions, H2O, Tris, Acrylamide/Bisacrylamide were mixed and 
degassed before addition of SDS, Ammoniumpersulfate and TEMED. Upon pouring 
the separation gel, a layer with butanol was added on top of the gel to prevent it from 
drying while polymerising. The butanol layer was meticulously washed off with 
distilled water before pouring the stacking gel on top of the separation gel. 
 
Loading dye (4 x) 
Tris HCl pH 6.8   0.25 M 
SDS      8% 
Glycerine    40% 
Bromphenolblue   0.02% 
Mercaptoethanol   400 mM 
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Running buffer (5 x) 
Tris Base    123.8 mM 
Glycine    959.1 mM 
SDS     17.3 mM 
 
Transfer buffer: 
Glycine    39 mM 
Tris Base    48 mM 
SDS     0.037% 
MeOH    10% 
 
Tris buffered saline (TBS) (10 x) 
Tris     24.2 g 
NaCl     58.44 g 
Distilled H2O    ad 1000 ml 
 
Tris buffered saline with Tween (TBS/T) 
TBS     1 x 
Tween 20    0.1% 
pH 7.6 
 
Blocking Buffer A 
NaCl     200 mM  
Tris pH 7,5    50 mM   
Bovine serum albumine (BSA) 3% 
Tween 20    0.05% 
Horse serum    10%  
 
Blocking Buffer B 
Tris     500 mM 
NaCl     1.5 M 
Non fat dry milk   5%  
pH 7.5 
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Blocking buffer C 
Tris    500 mM 
NaCl    1.5 M 
Non fat dry milk   3%  
Blocking buffer D 
Non fat dry milk powder  3% in TBS/T 
 
Blocking buffer E 
Bovine serum albumine (BSA) 5% in TBS/T 
 
Stripping buffer 
Glycine   0.2 M 
NaCl    0.5 M 
in PBS 
pH 2.9  
Primary antibody solutions 
Table 2: Primary antibodies used in western blot (MC: monoclonal, PC: polyclonal) 
Antibody Host Dilution and buffer Company 
Anti-SHP-2 (B-1) Mouse (MC) 1:500 
C 
Santa Cruz, Heidelberg, DE 
Anti- p85 (B-9) Mouse (MC) 1:500 
D 
Santa Cruz, Heidelberg, DE 
Anti-p42/44 
(Thr202/Tyr204) 
Mouse (MC) 1:1000 
A 
Cell signalling, Frankfurt a. Main, DE 
Anti-pRaf 
(Ser338) 
Rabbit (MC) 1:1000 
E 
Cell signalling, Frankfurt a. Main, DE 
Anti-pAkt 1/2/3 
(Thr308) 
Rabbit (PC) 1:500 
A 
Santa Cruz, Heidelberg, DE 
Anti-GAPDH Mouse (MC) 1:10 000 
D or E 
Chemicon, Hamshire, GB 
Anti-Actin 
(I-19) 
Goat (PC) 1:500 
B 
Santa Cruz, Heidelberg, DE 
Anti-pTyr  
(clone 4G10) 
Mouse (MC) 1: 1000 
A or E 
Biomol, Hamburg, DE 
Anti-Gab-1 Rabbit (PC) 1:1000 
E 
Cell signalling, Frankfurt a. Main, DE 
Anti-pSHP-2 
(Tyr 542) 
Rabbit (PC) 1:1000 
D 
Biomol, Hamburg, DE 
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Secondary antibody solutions 
Table 3: Secondary antibodies used in western blot 
Antibody Host Dilution Company 
Anti rabbit Goat 1:10 000 Calbiochem, Schwalbach, DE 
Anti mouse Goat 1:10 000 Calbiochem, Schwalbach, DE 
Anti goat Rabbit 1:10 000 Calbiochem, Schwalbach, DE 
MC: monoclonal, PC: polyclonal 
 
Experimental procedure 
Proteins were thawed on ice and 25-40 µg were mixed with 1 x loading dye (0.25 M 
Tris pH 6.8, 8% SDS, 40% Glycerine, 0.02% bromphenolblue, 400 mM 
mercaptoethanol), denaturated at 100 °C for 5 minutes before separated on a 10% 
SDS-PAGE consisting of a 4% stacking gel and a 10% separation gel covered in 
1 x running buffer. The current was set to 35 mA and the proteins were left to run 
until the loading dye front was approximately 1 cm from the edge of the gel. The 
separated proteins were then transferred onto a nitrocellulose membrane by 
electrophoresis using semi-dry blotting. For this, the nitrocellulose membranes 
together with filter papers were soaked in transfer buffer. The membrane and filters 
were stacked as a “sandwich” in the following order: filter paper, membrane, gel and 
filter paper. To check for equal amounts of protein and successful blotting, the 
membrane was incubated with Poinceau S solution (Sigma-Aldrich, Taufkirchen, 
Germany) which was removed by washing before further handling. To prevent 
unspecific binding of the antibodies the membrane was blocked with a blocking buffer 
depending on the antibody to be used (see table 2) for 30 minutes prior to a 1 hour 
incubation with the primary antibody diluted in their respective blocking buffer 
(according to table 2) at 37 °C or at 4 °C over night. Unbound antibody was removed 
by washing 3 x 5 minutes with TBS/T. The membrane was then incubated for 1 hour 
at room temperature or at 4 °C over night with a secondary antibody conjugated with 
horseradish peroxidase. After washing three times as described above, the enzyme 
activity was detected upon addition of chemiluminescence detection kit for 
horseradish peroxidase according to the supplier’s protocol with a bioluminescence 
detection system attached to a digital camera (Sequoia). 
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2.4.2. Immunoprecipitation of p-85 and SHP-2  
Materials 
Lysis buffer    See under section 2.3.3 
Loading dye    See under section 2.4.1 
Anti-SHP-2 antibody  0.5 µg/100 µg protein 
Anti-p85 antibody   0.5 µg/100 µg protein 
Protein G microbeads  50 µl/sample 
 
Cells 
HMEC 
 
Experimental procedure 
Immunoprecipitations were performed using µMACS Protein G Microbeads and 
MACS separation columns according to the manufacturer’s protocol. Shortly, equal 
amounts of protein from endothelial cells were incubated for 2 hours at 4°C with a 
mouse monoclonal p85 or SHP-2 antibody (both 0.5 µg/100 µg protein) followed by 
30 minutes incubation with Protein G microbeads (50 µl/ sample) on ice. The 
precipitates were purified by application onto the separation columns and washed 
three times with lysis buffer. Finally, the precipitates were detached from the 
microbeads by application of hot loading dye and the eluate collected in eppendorf 
tubes. Proteins were detected with western blot (see section 2.4.1) using a mouse 
monoclonal phosphotyrosine, mouse monoclonal p85 or rabbit polyclonal Gab-1 
antibody respectively.  As a control for equal amounts of precipitated protein, the 
precipitated protein itself was detected.                                                                                            
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2.5. FUNCTIONAL ASSAYS 
2.5.1. Treatment with growth factors and pharmacological inhibitors 
Growth factors and concentrations used 
VEGF-A165  10 ng/ml 
bFGF   10 ng/ml 
PDGF-BB  10 ng/ml 
 
Inhibitors  
Inhibitor (Name) Inhibiting protein Concentration 
used 
Incubation time 
Wortmannin PI3-Kinase 10 nM 30 minutes 
GW 5074 Raf-1 5 µM During the whole 
experiment 
Protein tyrosine phosphatase 
Inhibitor IV (Ptp I IV) 
SHP-2 2 µM During the whole 
experiment 
 
Activators 
Activator Activating protein Concentration 
used 
Incubation time 
Phorbol-myristate-acetate (PMA) Protein kinase C 1 µM 10 minutes 
  
Media 
HMEC starvation medium (1%) 
HUVEC starvation medium (1%) 
PAEC starvation medium (1%) 
 
Experimental procedure 
To investigate the effect of growth factors in SHP-2 signalling, HUVEC were starved 
in HUVEC starvation medium (1%) for approximately 12 hours and HMEC were 
starved in HMEC starvation medium (1%) for 24 hours and PAEC were starved in 
PAEC starvation medie (1%) during the whole experiment. bFGF, VEGF-A165 and 
PDGF-BB in starvation media were added to the cells and after incubation in a 
humidified incubator for 10 minutes, the cells were lysed as described in section 
2.3.3. When using pharmacological inhibitors, the cells were starved as described 
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above, treated with the inhibitors followed by incubation with the above mentioned 
growth factors. For experiments over 24 hours, the different growth factors and 
inhibitors were mixed with the respective starvation media and added to the cells 
every 24 hours. 
 
2.5.2. Protein activity assays 
Buffers and solutions 
 
Phosphatase buffer 
HEPES    20 mM    
NaCl     100 mM  
MgCl2     5 mM 
pH 6.5 
 
p-Nitrophenyl phosphate (pNPP) solution 
pNPP     5 mg (1 tablet) 
in 1.2 ml phosphatase buffer 
 
Other reagents 
Protein G on cross-linked beaded agarose  10 µl/100 µg protein 
Mouse monoclonal SHP-2 antibody   0.2 µg antibody/100 µg protein 
p-Nitrophenyl phosphate  (pNPP)   10 mM   
Sodium orthovanadate (Na3VO4)    1 mM 
bFGF, PDGF-BB and VEGF-A165    10 ng/ml 
 
Cells 
HMEC 
HUVEC 
 
Experimental procedure 
For SHP-2 phosphatase activity measurements, HUVEC were treated with 10 ng/ml 
bFGF, PDGF-BB and VEGF-A165, washed once with ice-cold PBS+ and lysed as 
described in section 3.2.3. To remove proteins binding unspecifically to the protein G 
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beads, equal amounts of protein were mixed with Protein G on cross linked beaded 
agarose and incubated at 4 °C for 30 minutes followed by centrifugation at 2500 rpm 
for 5 minutes at 4 °C. The supernatant was incubated with mouse monoclonal SHP-2 
antibody at 4 °C for 2 hours followed by addition of Protein G agarose beads and 
another incubation at 4 °C for 2 hours. The lysates were then transferred to a column 
containing 35 µm pore size filter (Mo Bi Tech, Göttingen, Germany) and washed 5 x 
with lysis buffer without any detergents. The filters were incubated with 10 mM pNPP 
(a phosphatase substrate producing a yellow end product), for 1 hour at 37 °C in the 
dark. The pNPP solution was then transferred to a 96 well plate and the colour 
intensity of the end product read spectrophotometrically at 405 nm with SpectraFluor 
(Tecan, Crailsheim, Germany) as a measurement for SHP-2 phosphatase activity. To 
obtain the inducible SHP-2 activity fraction, the filters were incubated with 1 mM 
Na3VO4 for 30 minutes at 37 °C before a second incubation with pNPP and 
subsequent measurement at 405 nm. The results obtained from this treatment were 
used as a background and substracted from the data obtained from the first 
measurement. 
 
For measuring Raf-1, ERK1/2 and Akt activity, the endothelial cells were starved for 
24 hours with HMEC starvation medium (1%) followed by treatment with bFGF, 
PDGF-BB or VEGF-A165, lysed and the lysate submitted to western blotting as 
described in sections 2.3.3 and 2.4.1 respectively. Membranes were first incubated 
with the respective phospho-antibodies and after visualisation of the protein bands 
stripped with stripping buffer (see section 2.4.1) for 1 hour followed by incubation with 
an anti-GAPDH antibody to ensure equal protein loading. For PI3-Kinase activity, cell 
lysates were precipitated with a p85 antibody as described in section 2.4.2, subjected 
to western blotting and subsequently immunoblotted with a phospho tyrosine 
antibody.  The band densities were measured as described in section 2.3.2 and the 
phospho-protein band normalised to the GAPDH or p85 band respectively for 
comparison of protein band densities. 
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2.5.3. In vitro wound healing assay 
Materials 
bFGF, PDGF-BB,VEGF-A165    10 ng/ml 
GW 5074     5 µM 
Ptp I IV     2 µM 
Collagen G     10 µg/ml 
 
Buffers and solutions 
HMEC starvation medium (1%) 
HUVEC starvation medium (1%) 
PAEC starvation medium (1%) 
 
Cells 
HMEC 
PAEC 
 
Experimental procedure 
To evaluate the effect of SHP-2 and Raf inhibition on endothelial wound healing in 
vitro, a standardised scratch assay was used. In detail, HMEC and PAEC were 
seeded onto Collagen G and following 24 hours of starvation in HMEC or PAEC 
starvation medium (1%) the cell layer was scratched once from edge to edge of the 
culture dish using a 0.5 mm pipet tip to obtain a standardized scratch through the 
otherwise confluent cell layer (Fig. 2.1). The cells were then incubated in HMEC or 
PAEC starvation medium (1%) to which bFGF, PDGF-BB, VEGF-A165 and the Raf 
inhibitor GW 5074 or the SHP-2 inhibitor (Ptp I IV) had been added. Photos of the 
scratches were taken at 0, 24, 48 and 72  hours after scratching with a LSM 410 
inverted laser scan microscope (Zeiss, Jena, Germany) using a 10 x 0.25 Ph1Var1 
objective at room temperature. The level of wound healing was determined by 
measuring the width of the scratches (in µm) at three different points/photo, to 
achieve a mean of scratch width, with the software simple PCI. 
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2.5.4. Cell proliferation assay 
Solutions 
 
Colourless DMEM (1%)  
Dulbeccos´s modified Eagle´s medium (DMEM) without phenolred 
Fetal calf serum (FCS)    1% 
Penicilline (10 000 U) / Streptamycine (10 mg) 1% 
L-Glutamine      2 mM 
 
Gelatine solution 
Gelatine      10 µg/ml 
in PBS – 
The solution was autoclaved for sterilization prior to use. To coat the 24 well plates 
with gelatine, sufficient amounts of the gelatine solution to cover the bottom of each 
well were added to the well plates. After incubation over night at 4 ˚C or for 30 
minutes in a humidified incubator, each well was washed three times with PBS+. 
 
 
 
 
 
 
µm 
200 µm 
Fig. 2.1 Scratch 
A scratch was performed using a 0.5 mm 
pipet tip on a confluent cell layer. The cell 
layer was scratched once from edge to 
edge of the culture dish. Photos were 
taken immediately after scratching and at 
24, 48 and 72 hours. The width of the 
scratch was measured at three different 
points (dashed lines) and a mean of 
scratch width / scratch was calculated. 
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Methylthiazoletetrazolium (MTT) solution 
MTT     5 mg/ml 
in PBS+ 
For every experiment, the MTT solution was freshly made in sufficient amounts to 
last for the whole time period of the experiment. Before application to the cells, the 
MTT solution was diluted further (1:10) in colourless DMEM (1%). 
 
Other reagents 
bFGF, PDGF-BB, VEGF-A165   10 ng/ml 
GW 5074    5 µM 
2 Propanol    100% 
SHP-2/Rdm AS-ODN  0.6 µg/well in a 24 well plate format 
 
Cells 
HMEC 
 
Experimental procedure 
To study their proliferation rate HMEC were seeded onto 24 well plates coated with 
gelatine and allowed to attach over night. The next day magnetofection was 
performed (according to table 1 in section 2.3.1) followed by serum starvation for 24 
hours prior to stimulation with bFGF, PDGF-BB and VEGF-A165 and the t=0 hour 
measurement. For experiments with GW5074, the cells were plated in medium 
containing 1% serum and treated with the inhibitor the following day. Proliferation 
was measured by the reduction of Methylthiazoletetrazolium, MTT, using the method 
described by Mosmann 131. Briefly, MTT is reduced to formazan by enzymes in the 
respiratory chain. Thus, the amount of formazan made is an indirect measure for the 
number of viable cells. The end product is coloured and can be measured 
spectrophotometrically at 595 nm. Briefly, cells were incubated with MTT for 2 hours 
at 37 °C and subsequently washed with PBS+. The formazan crystals formed by 
living cells were dissolved with 100% 2-Propanol and transferred to semi-micro 
cuvettes and measured with a spectrophotometer (Ultrospec 2000, Amersham 
Biosciences, Freiburg, Germany) at 595 nm and 650 nm. The amount of proliferation 
was determined by substracting the 650 nm value (background) from the 595 nm 
value. Data were normalized to the proliferative response, which was set to 100%, at 
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24 hours following seeding or transfection and before first growth factor treatment 
(t=0 hour measurement). 
 
2.5.5. Fluorescent-activating cell scanning analyses 
A flow cytometer can be used to assess information of the molecular properties of 
cells. By letting cells pass one at a time through a focused laser beam, the laser light 
is disrupted and scattered. This scattering of the light gives information about the cell 
size, so called forward scatter (FSC) and the internal complexity of a cell, such as the 
extent of granulation, called side scatter (SSC). In addition to scatter, a cytometer is 
also able to measure fluorescence using three detectors, FL1, FL2 and FL3. By 
staining cells with fluorescent dyes, such as propidium iodide or fluorochromes 
coupled to antibodies which recognize and bind cell surface antigens, a defined 
fraction of cells can be detected.  Data obtained in this study using fluorescent-
activating cell scanning were all measured with FACScan from BD Biosciences 
(Heidelberg, Germany). For measurements with endothelial cells, the signal for FSC 
was multiplied by 0.1 (setting E-1) and the level of amplification was set to 2.86. The 
detector level for SSC was set to 296 V and the level of amplification to 2.40. Both 
FSC and SSC were set to a linear data modus. From each sample 10 000 cells were 
projected through the laser beam and the data obtained were analysed with the 
CELLQuest software (BD Biosciences, Heidelberg, Germany). For the FACScan 
measurements in this study, following settings were used:  
 
Assay Stain 
(max exc, max em) 
Detector Detector level (V) Data mode 
Cell cycle  
(Propidium iodide, PI, staining) 
PI (530, 620) 
 
FL 3 380 Lin 
Apoptosis 
(Annexin V/PI) staining 
FITC (488, 520) 
PI (530, 620) 
FL 1 
FL 3 
480 
447 
Log 
Log 
Cell uptake of ODN  
(cy-3 labelled ODNs)  
Cy-3 (545, 560) FL 2 300 Log 
Cell viability (PI staining) PI (530, 620) FL 3 288 Log 
Lin: linear, Log: logarithmic; exc: excitation (nm), em: emission (nm) 
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2.5.6. Cell cycle measurement 
Buffers and solutions 
 
Propidium iodide solution 
Triton X-100   0.1% 
Rnase Inhibitor 2  5000 U 
Propidium iodide  0.6 mg 
HEPES   ad 50 ml H2O 
 
Other reagents 
SHP-2/Rdm AS-ODN 0.6 µg/well in a 24 well plate format 
 
Cells 
HUVEC 
 
Experimental procedure 
The DNA amount of cells can be used to define the different stages in the cell cycle, 
as the amount of DNA in a cell corresponds to where in the cell cycle the cell is 
residing. The cell cycle stage where the cells contain the least amount of DNA in 
comparison to the other stages is the G1-phase. Cells undergoing apoptosis are 
subdued to DNA fragmentation and because they also have a disrupted cell 
membrane these DNA fragments leak out of the cell. When staining cells with 
propidium iodide, which intercalates into the DNA, the cell membrane needs to be 
disrupted for the dye to enter the cell. The DNA of viable cells is normally too bulky to 
escape from the cell, in contrast to the DNA fragments seen in apoptotic cells, and 
high amounts of propidium iodide can therefore accumulate in the DNA of viable 
cells. Thus, a cell undergoing apoptosis takes up less amounts of propidium iodide 
than a cell in the G1-phase of the cell cycle. The apoptotic cell can so be detected in 
the so called SubG0-fraction. To analyse cell viability, cell cycle states of HUVEC 
were assessed by flow cytometric measurement of propidium iodide stained DNA as 
described by Crompton et al 132.  Briefly, 6, 24 and 48 hours after AS-ODN treatment 
(according to table 1 in section 2.3.1), the cells were detached by trypsination for 
approximately 2 minutes. The cell suspension was collected and the cells pelleted by 
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centrifugation at 2000 rpm (EBA 12 centrifuge from Hettich, Tuttlingen, Germany) for 
3 minutes at room temperature followed by resuspension in PBS+ (100 µl) and 
propidium iodide staining solution (900 µl). After 20 minutes incubation in the dark at 
room temperature, the DNA content of the cells was analysed by fluorescent-
activated cell scanning (FACScan) (for detailed settings see section 2.5.5). Cells 
detected in the Sub G0 fraction (the fraction with least amount of DNA due to DNA 
fragmentation) were assumed to include the fraction of apoptotic cells.  
 
2.5.7. Apoptosis measurements 
Reagents 
SHP-2/Rdm AS-ODN  0.6 µg/well in a 24 well plate format 
Annnexin V Apoptosis detection kit 1 containing: 
 Propidium iodide solution 
 Binding buffer (10 x) 
 Annexin V-FITC labelled antibody 
 
Cells 
HUVEC 
 
Experimental procedures 
To assess the amount of intact, yet apoptotic cells, an Annexin V / Propidium Iodide 
apoptosis assay kit was used according to the manufacturer’s protocol. Shortly, 6, 12 
and 24 hours following AS-ODN transfection (according to table 1 in section 2.3.1), 
HUVEC were washed with PBS+ and 5 µl propidium iodide solution was added to 
each well in a 24 well plate followed by incubation at 37 °C for 30 minutes. After 
rinsing the cells with PBS+ they were incubated with Accutase until all cells had 
detached from the plate. The cells were then separated from the solution by 
centrifugation at 2500 rpm for 3 minutes at room temperature. The pellet was 
subsequently resuspended in 1 x binding buffer whereupon 5 µl of annexin V-FITC 
(fluorescein isothiocyanate) labelled antibody was added. After incubation in the dark 
for 15 minutes and addition of 400 µl binding buffer flow cytometric analysis of cells 
staining positive for Annexin V but negative for propidium iodide was performed to 
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identify the fraction of cells undergoing early apoptosis (for detailed settings see 
section 2.5.5). 
 
 
2.5.8. Capillary like structure assay 
Buffers and solutions 
HUVEC growth media (20%) 
HUVEC starvation media (1%) 
 
Other reagents 
Ptp Inhibitor IV    2 µM 
SHP-2 AS-ODN    1 µg/60 mm cell culture dish 
Growth factor reduced Matrigel matrix 
 
Cells 
HUVEC  
 
Experimental procedure 
To investigate the effect on tube formation, confluent HUVEC were starved with 
medium containing 1% serum and treated with sham solution or Ptp Inhibitor IV (Ptp I 
IV) for 6 hours prior to trypsination and collection of the cells. The cells were then 
resuspended in medium containing 1% serum and Ptp I IV or sham solution and 
equal amounts of cells were seeded onto wells in a 24 well plate format filled with 
growth factor reduced Matrigel matrix. For SHP-2 AS-ODN treatment (according to 
table 1 in section 2.3.1), the cells were left in medium containing 20% serum for 6 
hours following transfection prior to seeding equal amounts / well of cells onto 
matrigel. HUVEC were left to form capillary like structures over night. For analysis, 
pictures of four predefined sectors (regions of interest) per well were taken the next 
morning with a LSM 410 inverted laser scan microscope (Zeiss, Jena, Germany) 
using a 10 x 0.25 Ph1Var1 objective at room temperature. For evaluation the 
capillary like structures in each sector were counted manually and blindfolded. The 
sum of capillary like structures in the four sectors was used for further evaluation and 
statistics. 
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2.5.9. Aortic ring sprouting 
Buffers and solutions 
Sodium pentobarbital (Narcoren) 
Tutofusin Voll-E® 
HUVEC growth medium (20%)  
 
Other reagents 
Growth factor reduced Matrigel matrix 
Protein phosphatase Inhibitor IV   2 µM  
 
Experimental procedure 
To investigate the effect of SHP-2 inhibition on proper vessel formation, the number 
of new vessels sprouting from a mouse aorta was evaluated. For this, adult Black6 
mice of both genders, bred and kept according to the German law of animal 
protection (TierSchG) paragraphs §1, §2 and §2a, at the animal department of the 
Institute of Physiology Munich, Germany were used. The mice were euthanized with 
an overdose of sodium pentobarbital (Narcoren) and the aorta was dissected and 
cleaned from fat and connective tissue. To be able to wash the lumen of the vessel to 
remove the remaining blood, the aorta was cannulized using a polyethylene tube 
before it was cut out of the corpse. After carefully rinsing the aorta with physiological 
solution (Tutofusin Voll-E®), it was kept in HUVEC growth medium (20%) while being 
manually cut into small rings. The aortic rings were embedded in growth factor 
reduced Matrigel matrix, and incubated at 37 °C for 30 minutes to allow the matrigel 
matrix to become hard. The embedded aortic rings (Fig. 2.2) were then treated with 
and kept in Ptp I IV diluted in HUVEC growth medium (20%). The aortic rings were 
left for 72-96 hours before pictures were taken with a LSM 410 inverted laser scan 
microscope (Zeiss, Jena, Germany) using a a 10 x 0.25 Ph1Var1 objective at room 
temperature. As a measurement of angiogenesis the bifurcations of the new vessels 
were counted manually. 
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2.6. STATISTICAL ANALYSIS 
All statistical analyses were performed using Sigma Stat version 2.0. For 
comparisons of two normally distributed groups of data, the Student’s t-test was 
used. For multiple comparisons of normal distributed data the one-way analysis of 
variance (one-way ANOVA) was used. The Mann-Whitney Rank sum test was 
performed when comparing two groups which were not normally distributed, whereas 
comparisons between several groups not exhibiting normal distribution was achieved 
by analyzing the data with the analysis of variance on ranks. For descriptive 
purposes all data are presented as means ± the standard error of means. Results 
were considered significant at an error probability level of p<0.05. 
 
 
Fig. 2.2 Aortic Ring 
A representative photo of an aortic ring 
96 hours after embedment in Matrigel. 
White arrows point at bifurcations of 
formed sproutings. 
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3. RESULTS 
The most exciting phrase to hear in science, 
the one that heralds new discoveries, is not Eureka! (I found it!) 
but rather, “hmm….that´s funny….” 
˜Isaac Asimov˜ 
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3.1. SHP-2 PROTEIN KNOCK-DOWN 
3.1.1.  Efficiency of AS-ODN transfer 
A formulation of antisense- oligodesoxynucleotides (AS-ODN) and the transfection 
reagent Effectene combined with magnetofection in HMEC showed a transfection 
efficiency of 86 ± 2% as assessed by transfection of Cy3-labelled Rdm ODN.  In 
contrast, only 26 ± 3% cells had taken up the AS-ODN when a transfection solution 
without magnetic particles was used. This complied with a 3.3 fold increase of 
transfected cells (p<0.01; n=6-9, grey bar in fig. 3.1A) when using magnetofection. 
Moreover, cell viability among the transfected cells did not differ significantly between 
the two groups as assessed by propidium iodide staining 24 hours post transfection. 
The group treated with the mixture of AS-ODN, Effectene and magnetic particles 
exhibited 19 ± 4%  (n=6-9) non-viable cells as compared to 14 ± 5% (n=6-8) non 
viable cells among the fraction of cells treated with the transfection mixture but 
without the influence of magnetic particles (Fig. 3.1A, dot plot). 
 
Cellular distribution and uptake were further confirmed with fluorescence microscopy 
of cells transfected with Cy-3 labelled Rdm ODN. 4 hours following transfection some 
of the Cy-3 labelled Rdm ODN could be observed in the cytosol but most of the Rdm 
ODN seemed to still reside on the cell surface. 16 hours post transfection, the 
highest amount of Rdm ODN could be observed in the cytosol and to a lesser extent 
in the nuclei. 24 hours after transfection the highest fluorescence could still be 
detected in the cytosol, although more Cy-3 labelled Rdm ODN could be observed in 
the nuclei in comparison to 16 hours following transfection (Fig. 3.1B). 
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Fig. 3.1 Transfection efficiency and cytotoxicity of antisense magnetofection 
Cells were incubated with the Effectene mixtures with (grey bar) or without (white 
bar) TransMAGPEI particles for 15 minutes. The cells were exposed to the magnetic 
field and were then washed three times with PBS+, followed by further cultivation in 
HMEC medium. For FACS analysis of cellular uptake, the cells were detached from 
the cell culture dish 4 hours post transfection. For cytotoxicity measurement, the cells 
were detached from the culture dish using sodium citrate 24 hours following 
transfection and stained with propidium iodide. For FACS analysis cells were fixated 
in 2% formalin. (A) Antisense-ODN uptake was over 80% in cells transfected with 
TransMAGPEI in comparison to transfection without TransMAGPEI (**p<0.01, n=6-9). 
Cytotoxicity in both groups was below 20% (dot plots n=6-9, ns: not significant). 
Photos above bars show AS-ODN (Rdm ODN) accumulation after transfection with 
(left photo) and without (right photo)TransMAGPEI 4 hours post transfection. (B) 
Representative photos of cells transfected with Cy-3 labelled AS-ODN in combination 
with magnetofection (arrows point at nuclei). From top to bottom: 4 hours following 
transfection, most of the Rdm ODN seem to still be positioned at the cell surface; 16 
hours after transfection, the highest fluorescence was detected in the cytosol 
although some nuclear accumulation could be observed; 24 hours following 
transfection, a higher nuclear uptake was observed but the highest AS-ODN  
accumulation seemed to still be in the cytosol. 
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3.1.2. Kinetics of SHP-2 knock-down 
SHP-2 AS-ODN treatment of endothelial cells (HUVEC and HMEC) resulted in a 
marked decrease of SHP-2 protein content (normalised to actin which was used as 
loading control) as soon as 6 hours following magnetofection as compared to Rdm 
ODN treatment (HUVEC 37 ± 29% inhibition and HMEC 69 ± 15% inhibition, p<0.05, 
both n=3) as shown by detection of SHP-2 protein levels with western blot. This 
effect was even more explicit after 24 hours (HUVEC 68 ± 18% inhibition, p<0.01, 
n=6, and HMEC 69 ± 10% inhibition, p<0.01, n=7) showing that the SHP-2 AS-ODN 
successfully inhibits SHP-2 expression in both cell types (Fig. 3.2A and 3.2B). 
However, 48 hours post transfection (n=3), the effect of the AS-ODN could no longer 
be observed. Therefore, following experiments were performed within or shortly after 
6-24 hours following transfection. 
 
To verify the specificity of the SHP-2 AS-ODN, HUVEC and HMEC were transfected 
with the AS-ODN and the protein level of the Src homology 2 containing tyrosine 
phosphatase 1 (SHP-1), the closest SHP-2 homologue, was detected by western blot 
24 hours post transfection. No reduction in SHP-1 protein expression could be 
observed after SHP-2 AS-ODN treatment in neither of the cell types, showing that the 
mRNA targeting by the SHP-2 AS-ODN, in addition to be efficient in degrading 
SHP-2 mRNA, also is specific (Fig. 3.2C, both n=2). 
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Fig. 3.2 Knock down of SHP-2 protein expression by AS-ODN 
Cells were transfected with SHP-2 AS-ODN and Rdm ODN in combination with 
magnetofection as described in Materials and Methods section 2.3.1 and left in 
growth medium for 6, 24 and 48 hours respectively. After lysing the cells, SHP-2 
protein content was analysed by western blot as described in Materials and Methods 
section 2.4.1. As a loading control, staining of actin detecting the carboxy terminus of 
all human isoforms was performed. SHP-2 was successfully knocked down by SHP-2 
AS-ODN transfection combined with magnetofection in both HUVEC (A) and HMEC 
(B) 6 hours (HUVEC n=3; HMEC n=3, *p<0.05) and 24 hours  (**p<0.01, HUVEC 
n=6, HMEC n=7) following transfection. After 48 hours (both n=3), the inhibition of 
protein expression could no longer be seen. Representative western blots for 
independent experiments are shown above the graphs.  (C)The protein level of the 
SHP-2 homologue SHP-1 was not changed in either HMEC nor in HUVEC when 
transfecting cells with SHP-2 AS-ODN. The shown blots are representative for each 
(HMEC and HUVEC) two independent experiments (n=2). 
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3.2. SHP-2 AFFECTS IMPORTANT STEPS OF ANGIOGENESIS 
INITIATION 
3.2.1. SHP-2 inhibition suppresses basal endothelial 
proliferation/migration after wounding in vitro  
As a first step to elucidate if suppression of SHP-2 has any effect on endothelial 
angiogenic processes, the ability to migrate over and proliferate into a scratch 
performed on a confluent cell layer was evaluated. As seen in figure 3.3A and 3.3B 
untreated cells covered 75 ± 3% (n=3) of the scratch after 48 hours while cells 
treated with the SHP-2 inhibitor Ptp I IV only covered 41 ± 11% (n=3, p<0.05) of the 
scratch. After 72 hours still, there was a tendency, although not significant, towards a 
delayed growth over the scratch (both n=3). 
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Fig. 3.3 SHP-2 inhibition suppresses basal endothelial proliferation/migration 
after wounding in vitro 
Angiogenesis initiation was assessed by a wound healing assay as described in 
Materials and Methods section 2.5.3. For this HMECs were starved in HMEC 
starvation media (1%) and treated with the SHP-2 inhibitor Ptp I IV. As control a 
sham solution was used. (A) Inhibition of SHP-2 with the pharmacological SHP-2 
inhibitor Ptp I IV (2 µM) significantly delayed the ability of endothelial cells to grow 
over the scratch (at 48 hours, *p<0.05, n=3).  72 hours after wounding the delay was 
no longer significant (ns). Numbers above bars show original data of scratch width 
(µm) as mean ± SED meaning the width of the scratch, which was not covered with 
cells. (B) Representative photos of the scratches. From top to bottom: photo taken 
immediately after the scratch (0 h), photo of sham treated cells taken 48 hours later 
(48 h) and photo of Ptp I IV treated cells 48 hours after scratching (Ptp I IV 48 h). 
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3.2.2. SHP-2 protein knock-down inhibits endothelial basal 
proliferation 
Since the previous described scratch assay, during the used time period, does not 
solely measure the migration of cells, but also their proliferation, we investigated in a 
next step if SHP-2 AS-ODN had any effects on basal endothelial cell proliferation. 
For this, the reduction of MTT in HMEC was measured at 0, 24 and 48 hours. SHP-2 
AS-ODN treatment, but not Rdm ODN, caused a decline of the proliferation rate by 
48% (± 5%; p<0.01; n=12.Fig 3.4A) under unstimulated conditions. Moreover, this 
rate of proliferation was at all time points below the initial value at t=0 hours.  
 
This was confirmed when detecting the DNA content of HUVEC by propidium iodide 
staining. The amount of DNA in a cell correlates to the different stages of the cell 
cycle, (for a detailed description, see Materials and Methods section 2.5.6). By 
measuring the amount of cells situated in the G2/M-phase, the two last phases where 
G2 is the last check-point for the cells before they enter the M-phase (M, Mitosis) 
where they divide, an estimation of the proliferative rate can be made. 24 hours post 
SHP-2 AS-ODN treatment a significantly lower amount of cells in the G2/M-phase of 
the cell cycle could be observed in comparison with Rdm ODN treatment (Fig. 3.4B, 
p<0.01, n=5). 48 hours after SHP-2 protein knock-down this reduction of cells about 
to or undergoing mitosis was still there although not significant (Fig. 3.4B, n=3). 
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Fig. 3.4 SHP-2 protein knock-down inhibits basal endothelial cell proliferation  
Endothelial cell proliferation was assessed by measuring the reduction of MTT as 
described in Materials and Methods section 2.5.4. For this HMECs were starved in 
HMEC starvation media (1%) and treated with SHP-2 AS-ODN. As control Rdm ODN 
was used. The amount of cells in the G2/M-phase of the cell cycle was detected by 
propidium iodide staining and subsequent FACS analysis as described in Materials 
and Methods section 2.5.6. For this, HUVEC were transfected with SHP-2 AS-ODN 
or Rdm ODN and left in HUVEC growth medium (20%) until measurement. (A) 
Treatment with SHP-2 AS-ODN significantly reduced endothelial cell proliferation 
(**p<0.01; n=12). (B) 24 hours following SHP-2 AS-ODN transfection, a lower 
amount of cells was observed in the G2/M-phase of the cell cycle (**p<0.01; n=5). 48 
hours after transfection the reduction was no longer significant (ns, n=3). 
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3.2.3. SHP-2 protein knock-down impairs endothelial cell viability 
and induces apoptosis  
To investigate if the decreased proliferation of cells deprived of SHP-2 was due to 
apoptosis, the DNA content of HUVEC was measured by propidium iodide staining 
(for a detailed description, see Materials and Methods section 2.5.6). FACS analysis 
revealed the amount of DNA in the cells, which correlates to the different stages of 
the cell cycle. The DNA content in the SubG0 fraction, which is the fraction of cells 
with least amount of DNA due to DNA fragmentation, was measured as an index of 
apoptosis. Starting at 6 hours after transfection, SHP-2 AS-ODN treated cells gave 
rise to a non-significant peak in SubG0 compared to Rdm ODN transfected cells 
(Fig. 3.5A). At 24 hours following transfection this difference reached significance 
(p<0.01; n=6). Treatment with the SHP-2 inhibitor Ptp I IV likewise resulted in a 
significant higher amount of cells in the SubG0 fraction after 24 hours (Fig. 3.5B, 
p<0.05; n=10). In a further step to verify whether SHP-2 is involved in the control of 
endothelial apoptosis and to detect the proapoptotic cells, HUVEC were stained with 
propidium iodide (PI) and against the proapoptotic marker annexin V. The annexin V 
content was measured with FACScan and cells staining positive for annexin V but 
negative for PI were assumed proapoptotic. Following SHP-2 knock-down there was 
a significant increase in Annexin V positive / PI negative cells already 6 hours post 
transfection compared to Rdm ODN treated cells (by 23 ± 7%, p<0.05; n=8, 
Fig. 3.5C). 12 hours following SHP-2 AS-ODN treatment the amount of  annexin V 
positive / PI negative cells was still higher in comparison with Rdm ODN treatment, 
although not significantly. Analyses of untreated cells at both time points did not 
show a higher Annexin V/PI binding than Rdm ODN treated cells (n=9). 
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Fig. 3.5 SHP-2 inhibition increases the amount of cells in SubG0 and Annexin V  
antibody binding 
Endothelial cell survival was analysed by propidium staining of HUVEC DNA content 
as described in Materials and Methods section 2.5.6. The different stages of the cell 
cycle were visualised by flow cytometry 6 and 24 hours post transfection with SHP-2 
AS-ODN and Rdm ODN respectively. Cells detected in the SubG0 fraction were 
assumed apoptotic. Additional staining against the proapoptotic protein Annexin V as 
described in Materials and Methods section 2.5.7 and detection of cells positive for 
Annexin V but negative for propidium iodide stain were assumed proapoptotic. (A) 
Following SHP-2 AS-ODN transfection a significant increase in the subG0 fraction 
(**p<0.01; n=6, HUVEC, 24h after transfection) was observed compared to Rdm 
ODN treated cells. (ns: not significant). (B) Treatment with Ptp I IV gave rise to a 
higher peak in SubG0 in comparison to sham treated cells (at 24 hours, *p<0.05, 
n=10). (C) Annexin V antibody binding was increased in SHP-2 AS-ODN transfected 
cells in comparison to Rdm ODN transfected cells (*p<0.05; n=9). Non transfected 
cells (untreated) showed a similar annexin V/PI binding to Rdm ODN treatment 
(ns: not significant, n=9). 
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3.2.4. Growth factors enhance SHP-2 protein activity and induce 
phosphorylation of SHP-2 
Having observed that SHP-2 inhibition influences endothelial cell proliferation and 
migration under basal conditions and also affects the cell viability of endothelial cells 
although cultured in a growth promoting medium (HUVEC growth media 20%), we 
next questioned if SHP-2 influences cell signalling initiated by distinctive angiogenic 
growth factors. To investigate this, we choose to study SHP-2 under the influence of 
VEGF-A, bFGF and PDGF-BB, which are all growth factors critical for events 
contained in angiogenesis, such as endothelial cell survival, proliferation, migration 
and ultimately vessel sprouting 13,25,33,34. Firstly, we assessed the ability of these 
factors to enhance SHP-2 activity. HUVEC stimulated with VEGF-A, bFGF and 
PDGF-BB exhibited a higher SHP-2 activity than untreated cells. Stimulation for 10 
minutes with bFGF and VEGF-A significantly enhanced the phosphatase activity of 
SHP-2 (p<0.05, n=23 and n=21 respectively. Fig 3.6), whereas PDGF-BB stimulation 
was increased already after 2 minutes of stimulation (p<0.05, n=4). For this reason, a 
stimulation time of 10 minutes for bFGF and VEGF was used in the following 
experiments, if not stated otherwise. Although PDGF-BB induced its highest SHP-2 
activity after 2 minutes, a stimulation time of 10 minutes was used, as SHP-2 
associates with the PDGF receptor but effects further down in the signalling pathway 
were investigated. 
 
Tyrosine phosphorylation of SHP-2 has been described to be associated with an 
enhancement of SHP-2 activity upon some, but not all, growth factors 74. To 
investigate if SHP-2 is tyrosine phosphorylated by stimulation of VEGF-A, bFGF and 
PDGF-BB, cell lysates were objected to western blotting and the phosphorylated 
tyrosine residue 542 (Y 542) was detected. While PDGF-BB and VEGF-A application 
gave rise to a slightly stronger phosphorylation of Y 542 in comparison to non 
stimulated cells (both n=5), bFGF stimulation did not (n=5). In fact, bFGF stimulation 
resulted in an even lesser phosphorylation of Y 542 than observed in untreated cells 
(Fig. 3.6). 
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Fig. 3.6 SHP-2 phosphatase activity upon growth factor stimulation 
HUVEC were stimulated with bFGF, PDGF-BB and VEGF-A (each 10 ng/ml), lysed 
and SHP-2 protein precipitated as described in Materials and Methods section 2.5.2. 
The activity was measured by addition of pNPP. The phosphorylation of Y 542 on 
SHP-2 was detected by immunoblot with an α-phospho-Y 542 antibody. Stimulation 
with bFGF, PDGF-BB and VEGF-A (all 10 ng/ml) enhanced the phosphatase activity 
of SHP-2 (*p<0.05, **p<0.01; n=21, n=4, n=21 respectively) in comparison to 
untreated cells (n=27). SHP-2 was tyrosine phosphorylated on position Y 542 upon 
addition of VEGF-A and PDGF-BB, but not after bFGF stimulation. The western blot 
over the graph is representative for five independent experiments (n=5). 
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3.2.5. Inhibition of SHP-2 impairs growth factor enhanced 
endothelial proliferation/migration after wounding in vitro 
To elucidate if suppression of SHP-2 has any effect on growth factor dependent 
processes, which are prerequisites for angiogenesis such as endothelial proliferation 
and migration, a wound healing assay, where the ability of the cells to grow over a 
scratch in the presence of bFGF or PDGF-BB is evaluated, was used.  
 
In cell culture dishes to which bFGF and PDGF-BB had been added, the wound 
healing response was accelerated in comparison with non stimulated cells (both 
bFGF and PDGF-BB p<0.05; n=3). After 24 hours, the cell layer in dishes to where 
bFGF had been applied reached 88 ± 6% confluency and where PDGF-BB was 
present the cell layer covered 76 ± 3% (both p<0.05; n=3, Fig. 3.7A and 3.7C) of the 
scratch, whereas sham treatment resulted in 49 ± 5% scratch confluency (n=3). At 72 
hours the cell layer over the scratch was virtually completely re-established (94 ± 5% 
and 86 ± 6% respectively; p<0.05; n=3). However, treatment with the SHP-2 inhibitor 
Ptp I IV in the presence of bFGF and PDGF-BB delayed the wound healing response 
of the endothelial cells. Addition of the growth factors bFGF and PDGF-BB did not 
change the rate of growth in cells suppressed of SHP-2 as the scratch was still 
visible and only 52 ± 7% and 42 ± 5% respectively (both p<0.01; n=3, Fig. 3.7B and 
3.7C) of the scratch had been covered with migrating or proliferating cells after 48 
hours. After 72 hours there was still a tendency towards a difference in scratch 
confluency between cells treated with Ptp I IV in the presence of growth factors and 
cells stimulated with a growth factor only, although not significant.   
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Fig. 3.7 SHP-2 affects growth factor induced endothelial proliferation/migration 
after wounding in vitro 
Growth factor dependent endothelial cell migration and proliferation was assessed by 
studying the ability of HMECs to cover a scratch performed on a confluent cell layer 
under the influence of bFGF and PDGF-BB (each 10 ng/ml) as described in Materials 
and Methods section 2.5.3. (A) Stimulation with bFGF and PDGF-BB accelerated the 
wound healing of endothelial cells compared to non stimulated cells (both *p>0.05, 
n=3, 24 hours after scratching). At 48 and 72 hours, the difference in scratch 
confluency was no longer significant (ns, all n=3). (B) Treatment with Ptp I IV delayed 
the wound healing response of endothelial cells up to 48 hours following scratching 
(§§p<0.01 bFGF vs bFGF + Ptp I IV, n=3; **p<0.01 PDGF-BB vs PDGF-BB + Ptp I IV, 
n=3). After 72h there was no significant difference in confluency between the groups 
(ns, n=3). C) Table showing original data as mean ± SED of scratch width (µm), 
meaning the width of the scratched area which was not covered by cells (for 
evaluation see Materials and Methods section 2.5.3). 
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Fig. 3.7 SHP-2 affects growth factor induced endothelial proliferation/migration 
after wounding in vitro 
Growth factor dependent endothelial wound healing was assessed by studying the 
ability of HMECs to migrate and proliferate over a scratch performed on a confluent 
cell layer under the influence of bFGF and PDGF-BB (each 10 ng/ml) as described in 
Materials and Methods section 2.5.3. (D) Representative photos of scratches. Bars in 
photos represent 200 μm. From top to bottom: photos taken immediately after 
scratching (0h), photos of cells stimulated with either bFGF (left photo) or PDGF-BB 
(right photo) taken 48 hours later (48 h), photos of Ptp I IV and bFGF (left photo) or 
PDGF-BB (right photo) treated cells 48 hours after scratching (Ptp I IV 48 h). 
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3.2.6. Loss of SHP-2 prevents bFGF and PDGF induced endothelial 
cell proliferation 
We investigated in a next step if SHP-2 AS-ODN had any effects on growth factor 
dependent endothelial cell proliferation by measuring the reduction of MTT in HMEC 
at 0, 24 and 48 hours. Addition of bFGF and PDGF-BB enhanced the proliferation of 
endothelial cells by 37 ± 4% (p<0.05; n=12, Fig. 3.8A) and 31% ± 2% (p>0.01; n=12) 
respectively compared to sham treated cells. In contrast, stimulation with VEGF-A 
was not able to induce endothelial cell proliferation at any time point measured in 
comparison to sham treated cells (Fig. 3.8A, n=12). Treating cells with SHP-2 
AS-ODN significantly reduced cell proliferation despite the influence of bFGF (by 
41 ± 5% after 24 hours, p<0.01; n=11) and PDGF-BB (by 55 ± 7% after 24 hours, 
p<0.01; n=12) in comparison to Rdm ODN (Fig. 4.8B). This rate of proliferation was 
at all time points below the initial value at t=0 hour.  
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Fig. 3.8 SHP-2 suppresses growth factor induced endothelial cell proliferation 
Growth factor dependent endothelial cell proliferation was assessed by measuring 
the reduction of MTT in HMECs upon SHP-2 AS-ODN and Rdm ODN treatment and 
addition of bFGF, PDGF-BB and VEGF-A (each 10 ng/ml) as described in Materials 
and Methods section 2.5.4. (A) Stimulation with bFGF and PDGF-BB significantly 
enhanced the proliferation of endothelial cells after 48 hours (**p<0.01, *p<0.05, 
n=12), whereas stimulation of VEGF-A was unable to increase the proliferative rate 
of endothelial cells in comparison with non stimulated cells (ns: not significant versus 
non stimulated cells, n=12). (B) Treatment with SHP-2 AS-ODN reduced bFGF and 
PDGF dependent cell proliferation as soon as 24 hours post transfection in 
comparison to Rdm ODN treated cells (bFGF + SHP-2 AS-ODN: **p<0.01, n=11; 
PDGF + SHP-2 AS-ODN: §§p<0.01, n=12).  
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3.3. SHP-2 IS NECESSARY FOR COMPLETE VESSEL FORMATION 
3.3.1. Loss of SHP-2 impairs the ability of endothelial cells to form 
capillary like structures  
To investigate whether the decrease in proliferation and migration and the 
subsequent increase in apoptosis following SHP-2 deprivation would have an effect 
on endothelium dependent capillary formation and thus the initiation of new vessel 
formation, we performed Matrigel assays to assess growth factor dependent 
formation of capillary like structures from endothelial cells. To do so, cells were either 
treated with a pharmacological inhibitor (Ptp I IV) of SHP-2 or SHP-2 AS-ODN in 
separate experiments followed by plating equal amounts of cells onto 3-dimensional 
Matrigel, which is a proangiogenic matrix. Whereas sham or Rdm ODN treated cells 
formed organised networks of capillary like structures (Fig. 3.9A and 3.9B, upper 
photos respectively), cells treated with SHP-2 inhibitor or SHP-2 AS-ODN failed to do 
so (Fig. 3.9A and 3.9B, lower photos respectively). Instead they detached 
themselves from the matrix (seen as dark dots) and the capillary structures were 
incomplete. Inhibition of SHP-2 with AS-ODN showed a 45 ± 13% (3 ± 0.8 capillary 
structures/mm2, p<0.01; n=8) reduction in the number of capillary like structures 
compared to Rdm ODN treated cells (7 ± 0.7 capillary structures/mm2). Treatment 
with the pharmacological SHP-2 inhibitor also reduced the number of capillary like 
structures significantly with 55 ± 16% (4 ± 1.6 capillary structures/mm2, p<0.05; n=3) 
compared to sham treated cells (9 ± 0.5 capillary structures/mm2, Fig. 3.9C). 
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Fig. 3.9 Inhibition of SHP-2 impairs the ability of endothelial cells to form 
capillary like structures  
HUVEC treated with Ptp I IV (2 μM) or SHP-2 AS-ODN were seeded onto a Matrigel 
matrix and left to form capillary like structures over night as described in Materials 
and Methods section 2.5.8. The structures were quantified at 16 hours following 
seeding of the cells. (A) Representative photos of capillary like structures (indicated 
by arrows, black bars in both photos represent 200 μm) taken with a laser scan 
microscope. From top to bottom: Photo of sham treated cells, photo of cells treated 
with the SHP-2 inhibitor Ptp I IV. (B) Representative photos of capillary like structures 
formed by cells transfected with Rdm ODN (upper photo) and cells transfected with 
SHP-2 AS-ODN (lower photo).  
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Fig. 3.9 Inhibition of SHP-2 impairs the ability of endothelial cells to form 
capillary like structures  
(C) The ability to form capillary like sproutings in a human matrix and growth factor 
rich media was significantly diminished when HUVECs were treated in separate 
experiments with a specific inhibitor of SHP-2 (Ptp I IV, 2 µM) (*p<0.05; n=3) or 
SHP-2 AS-ODN (**p<0.01, n=8) compared to sham treated cells  or Rdm ODN 
treatment respectively.  
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3.3.2. Inhibition of SHP-2 negatively affects vessel sprouting ex vivo  
To further investigate if SHP-2 inhibition directly influences angiogenesis, new vessel 
sprouting from mouse aortas was used as a model. After dissection, cleaning and 
cutting of the aorta the aortic rings were embedded in Matrigel and covered with 
growth factor rich media. Upon sham treatment or treatment with the SHP-2 inhibitor 
(Ptp I IV), the aortic rings were left to form sproutings for approximately 72-96 hours.   
 
As seen in figure 3.10A and 3.10B SHP-2 inhibition impaired vessel sprouting. The 
number of bifurcations of the newly formed vessels were remarkably reduced upon 
SHP-2 inhibition (27 ± 7 bifurcations/aortic ring, p<0.05; n=10, Fig 3.10A) in 
comparison with sham treated aortic rings (59 ± 11 bifurcations/aortic ring, n=8). 
Furthermore, vessels growing from aortas treated with the SHP-2 inhibitor seemed to 
be much shorter than sproutings from sham treated aortic rings (Fig. 3.10B). 
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Fig. 3.10 SHP-2 inhibition negatively influences vessel outgrowth ex vivo 
Dissected mouse aortas were embedded in a Matrigel matrix and treated with Ptp I 
IV (2 µM) in a growth promoting medium as described in Materials and Methods 
section 2.5.9. The number of bifurcations of the newly formed vessels sprouting from 
the aorta was evaluated and used as an indicator of angiogenesis. (A) The number 
of bifurcations on the endothelial sproutings from mouse aortas were significantly 
lower upon SHP-2 inhibition (*p<0.05, n=10) in comparison to sham treated rings. (B) 
Representative photos of aortic ring sproutings taken 96 hours post embedment in 
Matrigel. Bars in both photos represent 200 μm and white arrows point at sprouting 
bifurcations. The upper photo shows a sham treated (Ctrl) aortic aortic ring and the 
lower photo shows an aortic ring which has been treated with the SHP-2 inhibitor Ptp 
I IV. 
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3.4. SHP-2 AND ENDOTHELIAL SIGNALLING 
3.4.1. SHP-2 inhibition abrogates bFGF, PDGF-BB and VEGF-A 
induced activation of the PI3-Kinase in endothelial cells 
To investigate the signalling steps regulated by SHP-2 during growth factor 
dependent endothelial cell activation, we assessed whether the PI3-Kinase / Akt 
pathway, which is a prominent regulator of the cell cycle and influences proliferation 
in endothelial cells 25,50, is influenced by SHP-2 knock-down. To do so, we first 
questioned, whether the p85 regulatory subunit of PI3-Kinase is a potential target of 
SHP-2. Tyrosine phosphorylation of the p85 subunit activates the enzyme, thus 
PI3-Kinase activity was assessed by immunoprecipitation of p85 followed by 
immunoblotting against phospho-tyrosine with an α-phospho-tyrosine antibody. The 
tyrosine phosphorylation of the p85 subunit was induced upon stimulation with bFGF, 
(n=4, p<0.05), PDGF-BB (n=6, p<0.01) and showed a tendency to increase after 
VEGF-A (n=6) stimulation (Fig. 3.11A). However, when inhibiting SHP-2 with 
AS-ODN this growth factor dependent phosphorylation had the tendency to decrease 
in comparison to Rdm ODN (n=3, n=3, n=2 respectively, Fig 3.11B).  
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Fig. 3.11 Inhibition of SHP-2 affects the tyrosine phosphorylation of p85 
HMEC were lysed as described in Materials and Methods section 3.3.3 and the 
activity of the PI3-Kinase was assessed by detecting the level of tyrosine 
phosphorylation of the regulatory subunit p85 through immunoprecipitation with an 
α-p85 antibody followed by immunoblotting against phospho-tyrosine (Materials and 
Methods section 2.4.2 and 2.5.2). (A) Stimulation with bFGF, PDGF-BB and VEGF-A 
all resulted in an increased tyrosine phosphorylation of p85 (bFGF *p<0.05, n=4; 
PDGF-BB **p<0.01, n=6 and VEGF-A n=6) compared to non stimulated cells. 
Representative western blots are shown above the graphs. (B) Inhibition of SHP-2 
protein expression by SHP-2 AS-ODN reduced the growth factor dependent p85 
phosphorylation and thus PI3-Kinase activity in comparison with Rdm ODN treatment 
(AS-ODN/bFGF n=3, AS-ODN/PDGF-BB n=3 and AS-ODN/VEGF-A n=2). 
Representative western blots are shown above the graphs. The significance between 
treatment groups in this experiment was not tested due to low number of n´s of 
western blots (n=2-3), for a more detailed explanation see discussion section 4.4. 
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3.4.2. SHP-2 interacts with the p85 subunit of PI3-Kinase and Gab-1 
upon growth factor stimulation 
Having observed that SHP-2 inhibition suppresses bFGF-, PDGF-BB- and VEGF-A 
dependent activity of PI3-Kinase through diminished tyrosine phosphorylation of p85, 
it was of interest to elucidate if SHP-2 may directly interact with the p85 subunit by its 
phospho-tyrosine residue. To investigate this, SHP-2 protein was immunoprecipitated 
followed by immunoblotting against p85. This revealed that, upon bFGF, PDGF-BB 
and VEGF-A stimulation, SHP-2 indeed associated with the p85 subunit of the 
PI3-Kinase (Fig 3.12, upper blot, n=3).  
 
The Grb-2 associated binder 2 (Gab-1) has been shown to bind growth factor 
receptors and associate with SHP-2 upon PDGF and EGF stimulation 91,92,99,133. To 
investigate whether SHP-2 binds Gab-1 upon growth factor stimulation in our 
experiments, and thus might form a signalling complex with SHP-2 and p85, SHP-2 
was immunoprecipitated and immunoblotting against Gab-1 was performed. After 
stimulation with bFGF, PDGF-BB and VEGF-A, SHP-2 could be observed as a 
binding partner of Gab-1 (Fig 3.12, lower blot, n=3). 
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Fig. 3.12 Growth factor induced interaction between SHP-2, p85 and Gab-1 
Protein interactions were investigated by precipitation of SHP-2 protein as described 
in Materials and Methods section 2.4.2, followed by immunoblotting against p85 and 
Gab-1 respectively. Addition of bFGF, PDGF-BB and VEGF-A resulted in the binding 
of more p85 and Gab-1 molecules to SHP-2 (western blots are representative for 
each three experiments, n=3) in comparison to non stimulated conditions.  
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3.4.3. SHP-2 activates Akt upon bFGF and PDGF-BB but not 
VEGF-A stimulation 
To further investigate if the effects on PI3-Kinase activation seen after SHP-2 protein 
knock-down actually influences PI3-Kinase dependent signalling, the phosphorylation 
and thus activation of Akt, one of the downstream targets of PI3-Kinase, was 
detected using an α-phospho-Akt (pThr308) antibody after stimulation with bFGF, 
PDGF-BB and VEGF-A. bFGF, PDGF-BB as well as VEGF-A significantly induced 
the activity of Akt, as seen by a strong enhancement in the phosphorylation level 
(bFGF p<0.05, n=11; PDGF-BB p<0.05, n=9; VEGF-A p<0.05, n=7; Fig. 3.13A). In 
contrast, inhibition of SHP-2 seemed to diminish the bFGF (n=6, p<0.05) and 
PDGF-BB (n=5, p<0.01) dependent Akt phosphorylation and hence led to less 
activation (Fig. 3.13B). Stimulation of Rdm ODN transfected cells with VEGF-A did 
not seem to enhance the Akt phosphorylation and SHP-2 AS-ODN treatment 
followed by VEGF-A stimulation did not cause any change in the Akt phosphorylation 
level in comparison to Rdm ODN (n=4).   
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Fig. 3.13 SHP-2 dependent Akt activation 
HMEC lysates were subjected to western blotting as described in Materials and 
Methods section 2.4.1 followed by immunoblotting against the phosphorylated form 
of Akt. (A) bFGF (n=11), PDGF-BB (n=9) and VEGF-A (n=7) stimulation (all 10 
ng/ml) signifcantly enhanced the Akt phosphorylation (all *p<0.05) compared to non 
stimulated conditions. A representative western blot is shown above the graph. (B) 
While transfection of HMEC with Rdm ODN followed by growth factor stimulation 
caused an increase in Akt phosphorylation, SHP-2 AS-ODN treatment diminished the 
bFGF (n=5, *p<0.05) and PDGF-BB (n=5, **p<0.01) dependent phosphorylation of 
Akt. No change in Akt phosphorylation upon VEGF-A treatment could be observed in 
Rdm ODN or SHP-2 AS-ODN transfected cells (n=4). Representative western blots 
are shown above the graphs. The significance between the different groups of this 
experiment was determined by calculating fold change relative to the respective Rdm 
ODN (not shown in the graph). 
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3.4.4. Raf inhibition impairs endothelial cell proliferation and 
migration 
In addition to the PI3-Kinase / Akt pathway, the Raf-MEK-ERK pathway has also 
been shown to be essential for endothelial cell proliferation, survival and 
angiogenesis in vivo 56,57,62,134. To assess the importance of the growth factor 
dependent activation of the Raf-MEK-ERK pathway in endothelial cells in our assays, 
endothelial cell migration and proliferation were evaluated after treatment with a 
pharmaceutical Raf inhibitor (GW5074) under the influence of bFGF, PDGF-BB and 
VEGF-A. When inhibiting the Raf-MEK-ERK pathway by using the Raf inhibitor 
GW5074 and measuring the MTT reduction, the bFGF (Fig. 3.14A) and PDGF-BB 
(Fig. 3.14B) induced proliferation was markedly diminished at 48 hours (bFGF OD 
0.22±0.03 versus bFGF+GW5074 OD 0.20±0.03, p<0.05, n=12 and PDGF OD 
0.16±0.02 versus PDGF+GW5074 OD 0.13±0.03, p<0.01, n=12) and 72 hours 
(bFGF OD 0.25±0.04 versus bFGF+GW5074 OD 0.14±0.02, p<0.01, n=12 and 
PDGF OD 0.16±0.02 versus PDGF+GW5074 OD 0.11±0.02, p<0.01; n=12). 
Interestingly, in contrast to the inhibition of SHP-2, GW5074 treatment under 
stimulation with bFGF was not associated with a loss in cell number until after 72 
hours, whereas GW5074 treatment under the stimulation of PDGF-BB was 
associated with a decline in cell number already at 48 hours. 
 
When investigating the effects of Raf suppression on endothelial wound healing by 
studying the ability of endothelial cells to cover a scratch performed on a confluent 
cell layer, inhibition of Raf with GW5074 strongly impaired the ability to grow over the 
scratch in the presence of all three growth factors in comparison to sham treated 
cells. Cells treated with bFGF, PDGF-BB and VEGF-A re-established the confluency 
of the scratched area already after 72 hours (by 87 ± 7%, 88 ± 2% and 96 ± 2% 
respectively, all n=3 compared to t=0 hours), whereas the scratch amongst the cells 
treated with the Raf inhibitor was visible still after 72 hours (bFGF/ GW 5074 
52 ± 6%, PDGF-BB/ GW 5074 29 ± 7 and VEGF-A/ GW 5074 38 ± 2% scratch 
confluency, all n=3 compared to t=0 hours) despite the presence of growth factors. 
This difference in scratch confluency between cells treated with growth factors and 
GW 5074 together with growth factors was significant after 48 hours (VEGF-A/GW 
5074 and PDGF-BB/GW 5074, both p<0.01, all n=3, Fig. 3.14C and 3.14D) and after 
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72 hours (VEGF-A/GW 5074, PDGF-BB/GW 5074 and bFGF/GW 5074, all p<0.01, 
all n=3, Fig. 3.14C and 3.14D). 
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Fig. 3.14 Proliferation and wound healing in vitro of endothelial cells is 
dependent on Raf  
HMEC or PAEC were treated with the Raf inhibitor GW 5074 (5 μM) together with 
either bFGF, PDGF-BB or VEGF-A. Proliferation and wound healing ability of 
endothelial cells was measured as described in Materials and Methods section 2.5.4 
and 2.5.3 respectively. (A) Treatment with GW 5074 in the present of bFGF lead to a 
decreased proliferation rate of endothelial cells (*p<0.05, n=12, HMEC at 48 hours 
after scratching and treatment) and resulted in a decrease in the cell number after 72 
hours (**p<0.01, n=12) in comparison to cells treated with bFGF only. (B) Application 
of GW 5074 and PDGF-BB resulted in a decreased cell number already after 48 
hours (*p<0.05, n=12) and continued to decline as seen at 72 hours (**p<0.01, n=12) 
compared to cells treated with only PDGF-BB. (C) Whereas cells stimulated with 
bFGF, PDGF-BB and VEGF-A (all 10 ng/ml) reached confluency again around 48 
hours or at 72 hours, cells treated with GW 5074 were not able to cover the scratch 
at such content (VEGF-A + Ptp I IV ##p<0.01, n=3; PDGF-BB + Ptp I IV **p<0.01, 
n=3; bFGF + Ptp I IV §§p<0.01, n=3, PAEC).  
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Fig. 3.14 Proliferation and wound healing in vitro of endothelial cells is 
dependent on Raf  
(D) Representative photos of scratches. Bars in photos represent 200 μm. From top 
to bottom: photos taken immediately after scratching (0 h), photos taken 48 hours 
after scratching (48 h) and stimulation with growth factors (from left to right: VEGF-A, 
bFGF, PDGF-BB), photos taken 48 hours after scratching and treatment with GW 
5074 and growth factors (from left to right: GW 5074/VEGF-A, GW 5074/bFGF, GW 
5074/PDGF-BB). 
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3.4.5. Growth factor dependent PI3-Kinase regulation of Raf and 
ERK activation 
Since we observed a marked effect on processes important for angiogenesis by 
inhibiting Raf in endothelial cells, it was of importance to investigate if there could be 
a direct link between SHP-2 and the Raf-MEK-ERK pathway. We hypothesized that 
PI3-Kinase may be an upstream regulator of the Raf-MEK-ERK pathway and thus 
the target affected by SHP-2 in these experiments. To investigate this, endothelial 
cells were treated with Wortmannin (10 nM), which inhibits PI3-Kinase activity, and 
subsequently stimulated with bFGF, PDGF-BB and VEGF-A before staining for 
phosphorylated Raf-1 and ERK 1/2. Inhibition of the PI3-Kinase by Wortmannin 
inclined a decrease in the Raf-1 (Fig. 3.15A, bFGF/Wortmannin n=5, 
PDGF-BB/Wortmannin n=4 and VEGF-A/Wortmannin n=4) and ERK 1/2 (Fig. 3.15B, 
all n=3) phosphorylation respectively regardless of growth factor stimulation. 
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Fig. 3.15 PI3-Kinase dependent Raf and ERK activation 
Wortmannin (10 nM, 30 minutes) treated HMEC lysates were subjected to western 
blotting as described in Materials and Methods section 2.4.1 followed by 
immunoblotting against the phosphorylated form of Raf-1 and ERK 1/2. (A) Inhibition 
of PI3-Kinase by the application of Wortmannin seemed to reduce the 
phosphorylation level of Raf despite bFGF (n=5), PDGF-BB (n=4) and VEGF-A (n=4) 
stimulation. Representative western blots from independent experiments are shown 
above the graph. (B) Wortmannin treatment also influenced the growth factor 
dependent activation of ERK 1/2. Western blot is representative for three 
independent experiments, n=3. 
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3.4.6. SHP-2 knock-down reduces growth factor induced ERK 
activation 
Finally, to elucidate if SHP-2 inhibition affects the activity of the Raf-MEK-ERK 
pathway, the phosphorylation and hence activation of the extracellular regulated 
kinase 1/2 (ERK1/2) upon growth factor stimulation was assessed by immunoblotting 
against phospho-ERK 1/2. bFGF, PDGF-BB and VEGF-A all induced a strong 
phosphorylation of ERK 1/2 (all p<0.05, bFGF n=15, PDGF-BB n=13 and VEGF-A 
n=17, Fig. 3.16A). However, upon transfection with SHP-2 AS-ODN the bFGF (n=7, 
p<0.05), PDGF-BB (n=5, p<0.05) as well as VEGF-A (p<0.05, n=5) dependent 
phosphorylation of ERK1/2 significantly decreased in comparison to Rdm ODN 
treatment (Fig. 3.16B).  
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Fig. 3.16 Reduction of growth factor induced ERK phosphorylation by SHP-2 
AS-ODN treatment 
HMEC lysates were subjected to western blotting as described in Materials and 
Methods section 2.4.1 followed by immunoblotting against the phosphorylated form 
of ERK 1/2. (A) Stimulation with VEGF-A (n=17), bFGF (n=15) and PDGF-BB (n=13) 
induced ERK1/2 activity (all *p<0.05). A representative western blot for independent 
experiments is shown above the graph. (B) SHP-2 knock-down seemed to reduce 
the bFGF (n=7, *p<0.05), PDGF-BB (n=5, *p<0.05) and VEGF-A (n=5, *p<0.05) 
dependent ERK phosphorylation. Representative western blot is shown above the 
graph. The significance between the different groups of this experiment was 
determined by calculating fold change relative to the respective Rdm ODN (not 
shown in the graph). 
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3.4.7. The effects of SHP-2 knock-down are specific 
It was important to ensure that the effects seen following SHP-2 inhibition were 
specific for SHP-2 knock-down and not just an overall reaction to apoptosis. Since 
treatment with Phorbol-myristate-acetate (PMA), a direct stimulator of Protein kinase 
C, for 10 minutes has been shown to activate the Raf-MEK-ERK pathway 
independent of SHP-2 activation 85, we choose to detect the phosphorylation of 
ERK1/2 in endothelial cells after SHP-2 AS-ODN treatment and subsequent 
stimulation with PMA. PMA stimulation of non transfected cells resulted in a robust 
activation of ERK1/2. In contrast to the bFGF and PDGF-BB dependent ERK 1/2 
activation, PMA-induced ERK 1/2 activation was independent of SHP-2, as AS-ODN 
against SHP-2 had no effect in these experiments (Fig. 3.17, n=4).  
 
 
Fig. 3.17 PMA induced activation of ERK1/2 despite SHP-2 AS-ODN treatment 
Non transfected and transfected HMEC were treated with PMA (1 μM, 10 minutes) 
and the lysates subjected to western blotting as described in Materials and Methods 
section 2.4.1. ERK phosphorylation was detected using an α-phospho-ERK 1/2 
antibody. Stimulation of non transfected cells with PMA resulted in a strong ERK 1/2 
phosphorylation (*p<0.05, n=4). SHP-2 protein knock-down did not reduce this PMA 
dependent ERK 1/2 activation (n=4, ns: not significant). Western blots above graph 
are representative for four independent experiments (n=4). 
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4. DISCUSSION 
“Science... never solves a problem without creating ten more.” 
˜George Bernard Shaw˜ 
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The process of angiogenesis is important not only during embryogenesis but also 
throughout life. Vital processes like wound healing and the reproductive cycle 1,3,135, 
but also pathological conditions such as tumour growth and ischemic diseases 6,7 
relay on angiogenesis. It is dependent on a variety of cytokines and growth factors, 
such as bFGF, VEGF-A and PDGF-BB important for the initiation of angiogenesis 
involving the prevention of apoptosis of endothelial cells and the stimulation of 
endothelial cell proliferation and migration 2 as well as for the later stages of this 
process involving organization of endothelial cells into tube-like structures followed 
by the extension and branching of these structures 8. Two signalling pathways highly 
involved in these events are the PI3-Kinase / Akt 50,51 and the Raf-MEK-ERK 
cascade 57. A tyrosine phosphatase, which has been implicated in the regulation of 
these pathways, is the Src homology 2 domain containing tyrosine phosphatase 2 
(SHP-2) 72. So far it has been unknown, however, if SHP-2 is involved in 
angiogenesis. Furthermore, the role of SHP-2 in endothelial angiogenic signalling 
had not been investigated until now. Finally, the type of regulation of the PI3-Kinase 
and the Raf-MEK-ERK pathway under the influence of VEGF-A, bFGF and PDGF-BB 
in human endothelial cells remained to be elucidated. Therefore, in this study we 
investigated the role of SHP-2 in these processes, which are prerequisites for 
angiogenesis such as endothelial cell survival and proliferation, but also in events 
necessary for proper vessel formation such as tube formation and vessel sprouting. 
Finally, we dissected the roles of SHP-2 in VEGF-A, bFGF and PDGF-BB enhanced 
signalling in human endothelial cells. 
 
 
4.1. SILENCING OF SHP-2 PROTEIN 
4.1.1. Why AS-ODN?  
It is difficult to develop specific inhibitors for tyrosine phosphatases, as these 
enzymes show a close similarity, particularly the phosphatase domains 70. The 
pharmacological inhibitors for SHP-2 existing today all inhibit, at lower or higher 
concentrations, other phosphatases to some extent. Therefore, to be able to 
specifically investigate the function of SHP-2, we chose to down regulate SHP-2 
posttranscriptionally with either AS-ODN or siRNA. Since not all sequences are 
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suitable for efficient PTGS, due to the secondary and sometimes the tertiary structure 
of the mRNA as well as the steric occlusion of a certain stretch of the mRNA by 
proteins or polycations 117, several different sequences for AS-ODN and siRNA were 
tried out in this study. Only one AS-ODN sequence was shown to be efficient, which 
was the reason for performing our experiments using an AS-ODN rather than siRNA. 
 
4.1.2. Specific knock-down of SHP-2 using the magnetofection 
method 
One difficulty with these agents has, so far, been the cellular uptake of the 
oligonucleotides in cultured cells. The most common method is to use liposomes or 
charged lipids which encapsulate or form a complex with the antisense molecule 116, 
but these procedures are time consuming and require a relatively high amount of 
oligonucleotides. By using the recently developed magnetofection technique, the 
transfection efficiency is enhanced in comparison to standard lipid transfection 
reagents 125. Furthermore, the time of transfection is reduced as well as the vector 
concentration 123-125, due to effective delivery of the oligonucleotides. The possibility 
of a rapid delivery of oligonucleotides at a low concentration reduces the cytotoxicity 
in comparison to other standard transfection reagents, where the cells need to be 
exposed to the transfection solution for a much longer time 125.  Transfection of a 
Cy-3 labelled ODN to HMEC using magnetofection in this study resulted in a 
transfection efficiency of over 80% while only 26% of the cells were observed to have 
efficiently taken up the Cy-3 ODN when magnetofection was not performed (Fig. 3.1). 
Furthermore, the cytotoxicity in both groups was similar (approximately 20%, 
Fig. 3.1), showing that magnetofection is a powerful tool that ensures an efficient 
delivery of ODN to endothelial cells, which are known to be almost transfection 
resistant. The positive results obtained from these measurements enabled us to use 
this technique for PTGS in this study. These results are in accordance to previous 
work performed by Krötz et al. 125, where magnetofection of AS-ODN into HUVEC 
also showed a transfection efficiency of over 80% with a cytotoxicity of less than 
10%. The explanation for the higher number of non viable cells observed in this study 
after magnetofection is most likely the higher concentration of ODN that was used. 
While Krötz et al. transfected cells with 0.2 µg AS-ODN/ well in a 24 well plate format, 
cells in this study were exposed to 0.6 µg ODN/ well in a 24 well plate format. The 
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reason for using a higher amount of ODN in these experiments is that the SHP-2 
protein was knocked-down reliably at this concentration only. The amount or 
concentration of the AS-ODN needed to silence the expression of a specific protein 
relies on the frequency and amount of the particular mRNA expression. Furthermore, 
the time needed from the point of transfection until a reduction in protein level can be 
observed depends on how fast the AS-ODNs reach the cytosol after having been 
deposited on the cell surface but more importantly on the turnover of the actual 
protein. In our experiments a knock-down of SHP-2 protein could be seen already 6 
hours post transfection and reached its maximum 24 hours after transfection 
(Fig. 3.2). After 48 hours the effect could no longer be seen. This correlates well with 
the Cy-3 ODN distribution in the cells observed in this study (Fig. 3.1B). 4 hours after 
transfection the Cy-3 ODN was seen to already reside in the cytosol and nothing or 
very little was detected in the nuclei. Most of the AS-ODN seemed to still be on the 
cell surface though, whereas 24 hours post transfection the AS-ODN could clearly be 
seen both in the cytosol and in the nuclei. The silencing of the SHP-2 mRNA was 
specific, as detection of SHP-1, which is the closest homologue to SHP-2, did not 
show any reduction in protein level.  
 
Another item one should take into account is that AS-ODNs have a restricted time of 
action, due to eventual degradation within the cell, which limits the duration of the 
silencing. These observations comply with previous data by Vickers et al, who used 
the endogenous mRNA for Bcl-X as target to investigate the duration of action of 
oligonucleotides. The highest efficiency of the AS-ODN was detected after 24 hours 
and was almost lost after 48 hours 121. Our results showed that AS-ODNs have an 
efficiency window of about 48 hours and that repeated transfections would be 
necessary if using this approach therapeutically when a sustained treatment is 
desired. 
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4.2. SHP-2 AS A POTENTIAL KEY PROTEIN IN THE ANGIOGENIC 
PROCESS 
4.2.1. Inhibition of SHP-2 suppresses both basal and growth factor 
induced endothelial response to wound healing in vitro 
Fibroblast cells lacking a functional SHP-2 have been shown to exhibit an impaired 
cell spreading and migration associated with an increased number of focal 
adhesions 136. In endothelial cells, SHP-2 has been shown to be involved in cellular 
adhesion processes by interaction with PECAM-1 and VE-Cadherin 103,104,107. SHP-2 
deficiency also associated with a decrease in focal adhesion kinase (FAK) activity 136. 
This has led to the suggestion that SHP-2 has a role in endothelial cell motility. 
Indeed, in our study inhibition of SHP-2 with the pharmacological inhibitor PtpI IV, in 
comparison to sham treated cells (Fig. 3.3), resulted in an incapability of endothelial 
cells to re-establish the cell layer after a wound incision, a process where adhesion 
molecules play an important role. Addition of the angiogenic growth factors PDGF-BB 
and bFGF could not reverse this effect (Fig. 3.7). Although application of these 
growth factors to PtpI IV treated cells enhanced the wound healing to some extent, it 
was still significantly delayed in comparison to cells treated with only PDGF-BB and 
bFGF. These first findings of this study lead to the assumption that SHP-2 influences 
processes important for angiogenesis initiation. 
 
4.2.2. SHP-2 knock-down results in a decreased endothelial cell 
proliferation 
Since the above described wound healing assay includes several steps such as 
endothelial cell migration and proliferation and one cannot distinguish between the 
two, in a next step the specific effect of SHP-2 on basal and growth factor induced 
endothelial cell proliferation was investigated. Interestingly, whereas addition of 
bFGF and PDGF-BB enhanced the proliferation of endothelial cells, addition of 
VEGF-A165 did not (Fig. 3.8A). This was surprising, since VEGF-A has been 
described as the primary angiogenesis inducer and as a potent stimulator of 
endothelial cell proliferation 24,25,137. There are several possible explanations for the 
inability to detect any increase in VEGF induced endothelial proliferation in this study. 
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Firstly, the studies showing a VEGF-A induced endothelial proliferation have been 
performed in HUVEC or PAEC, whereas HMEC were used for this assay in this work. 
HMEC were chosen for this assay due to their ability to survive in starvation media 
for a much longer time than HUVEC, which detached from the collagen coated cell 
dish already after 24 hours when used (data not shown). It is possible, that HMEC, 
which have been immortalized by the introduction of the large T antigen, exhibit a 
higher basal proliferative rate than primary endothelial cells and because of this need 
stronger stimuli, such as bFGF or PDGF-BB, than VEGF-A to accelerate their 
proliferation rate. Although VEGF-A is endothelium specific 2, it does not appear to be 
the most potent inducer of endothelial proliferation, as bFGF stimulation has been 
shown to increase the proliferation of endothelial cells over 2-fold, whereas VEGF 
treated cells only enhanced the proliferation by approximately 1.5 fold at 
concentrations ranging from 0.1 to 10 ng/ml 137. Secondly, the VEGF-R density might 
vary from primary endothelial cells to HMEC. However, functional effects observed 
after VEGF-A stimulation, such as ERK1/2 phosphorylation proved that there must 
be VEGF-R on HMEC. Thirdly, the VEGF-A peptide used in the experiment was only 
added to the cells every 48 hours, which might have been a too long time span. It is 
possible, that the peptide was degraded faster than the other growth factors und thus 
was unable to induce significant proliferation. 
 
Nevertheless, knock-down of SHP-2 showed a decreased proliferation both when 
measuring the reduction of MTT (Fig. 3.4A) and detecting the amount of cells 
situated in the G2/M-phase of the cell cycle (Fig. 3.4B). In addition to the diminished 
basal proliferation, the bFGF and PDGF-BB enhanced proliferation was also reduced 
when cells were treated with SHP-2 AS-ODN (Fig. 3.8B). Although studies on 
patients with Noonans syndrome indicate that SHP-2 is important for cellular 
proliferation, as these patients exhibit a higher risk of developing juvenile 
myelomonocytic leukaemia 76, which is characterized by a high proliferation rate of 
myeloid progenitor cells, and recent data show a reduction in self-renewal of SHP-2 
heterozygous hematopoetic stem cells 138, these are, to our knowledge, the first data 
showing a direct role of SHP-2 in bFGF and PDGF-BB induced endothelial cell 
proliferation. 
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4.2.3. Loss of SHP-2 impairs endothelial cell viability and induces 
apoptosis 
The reduction of MTT cannot only be used to measure the proliferation of cells but 
also is an indicator of cell viability, since it is reduced into formazan only in living 
cells. Whereas the formazan production in cells treated with Rdm-ODN in the 
absence of growth factors stayed constant throughout our experiments, cells 
transfected with SHP-2 AS-ODN exhibited a much lower formazan formation and as 
this was below the initial value at first measurement (Fig. 3.4A), it indicated that the 
reduction in the proliferative response may be due to an increased cell death. In 
addition, one important prerequisite for angiogenesis to occur is the prevention of 
endothelial apoptosis to allow for endothelial proliferation and migration under 
conditions that normally favours apoptosis, such as loss of contacts to the 
extracellular matrix. To test whether silencing of SHP-2 indeed would influence 
endothelial cell viability and thus be a necessary protein in preparing for 
angiogenesis to take place, the DNA content of endothelial cells was stained with 
propidium iodide. Cells detected within the SubG0 fraction were assumed apoptotic, 
as this population contains less DNA than cells situated in the G1 phase of the cell 
cycle due to DNA fragmentation. 24 hours after treatment with SHP-2 AS-ODN and 
PtpI IV a significantly higher peak in SubG0 could be detected, which was not seen in 
Rdm-ODN or Sham treated cells respectively (Fig. 3.5A and 3.5B). Since this assay 
does not detect the proapoptotic cells, an Annexin V staining was performed. 6 hours 
after treatment with SHP-2 AS-ODN treatment, an increase in Annexin V positive 
cells could be observed (Fig. 3.5C), which confirmed our previous results indicating 
that SHP-2 knock-down leads to an increased endothelial apoptosis. This also led to 
the conclusion that the reduction in growth factor induced endothelial proliferation 
most possibly was due to an enhanced apoptosis of endothelial cells, which could not 
be rescued by the addition of survival factors such as bFGF and PDGF-BB. Even 
though these results are in concordance with previous work showing a 
hypersensitivity of SHP-2 deficient fibroblasts towards an apoptosis inducing 
agent 96,97, they show for the first time the functional consequences of SHP-2 action 
in primary human endothelial cells. Moreover, these results further confirm our 
hypothesis that SHP-2 is necessary for events included in angiogenesis initiation, 
such as endothelial cell proliferation and cell survival. 
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4.2.4. SHP-2 and new vessel formation 
The previous observations pointing at a crucial role of SHP-2 in several of the 
processes needed for proper vessel formation incited us to investigate the effects of 
SHP-2 on the formation of capillary like structures by using a Matrigel assay. This is a 
critical step during angiogenesis where proliferating and migrating endothelial cells 
organize themselves into stable tubular structures. Treatment with the 
pharmacological SHP-2 inhibitor PtpI IV as well as with SHP-2 AS-ODN significantly 
impaired this process by a reduction in the number of capillary like structures with 
approximately 50% in comparison to sham or Rdm-ODN treated endothelial cells 
respectively (Fig. 3.9). This observation coincides with the finding that SHP-2 
negative mutant endothelial cells failed to organize themselves into a highly 
vascularized network in the yolk sac of mouse embryos 101.  
 
This assay has been described as one of the most specific tests for angiogenesis 
and is now widely used. One potential drawback of this assay is that other cells of 
non endothelial origin have been reported to also respond to Matrigel 139. Although 
the Matrigel used in our experiments was reduced of growth factors it still contained a 
small amount of growth factors such as bFGF, PDGF, EGF and IGF-1. As we wished 
to study the process of angiogenesis in an environment as close as possible to the in 
vivo situation, we treated the cells in the Matrigel with growth media supplemented 
with serum and additional growth media containing growth factors such as bFGF and 
EGF. As an inhibition of SHP-2 impaired the formation of capillary like structures 
even in the presence of several different growth factors, SHP-2 might also be 
important for endothelial signalling induced by other growth factors and may 
constitute a key position in growth factor dependent angiogenesis.  
 
Not only is the ability to form functional tubes important for later functional blood 
vessels, but also the capability of the formed tubes to bifurcate and extend. To study 
this process and to address the question if the effects seen after SHP-2 inhibition or 
knock-down have physiological consequences, such as impaired vessel sprouting, 
mouse aortas were cut into rings and embedded in a proangiogenic matrix. The 
sprouting of new vessels from these rings was impaired when treated with PtpI IV, as 
observed by the lower amount of sprouting bifurcations (Fig. 3.10). The observation 
that patients with NS often suffer from congenital heart disease 76 would support a 
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role for SHP-2 in blood vessel development. Indeed, our findings strongly confirmed 
the hypothesis that SHP-2 plays a major part, and for the first time dissect its role, in 
the process of angiogenesis. Moreover, the finding that SHP-2 homozygous knock-
out mice die in utero with an incomplete blood vessel development further strengthen 
our hypothesis 101. This puts SHP-2 in a completely new functional background. It not 
only affects the events crucial for angiogenesis initiation such as growth factor 
dependent endothelial cell survival, proliferation and migration but the impairment of 
these processes by inhibiting SHP-2 are also of functional significance, as this 
probably caused the improper vessel formation. 
 
 
4.3. THE ROLE OF SHP-2 IN ENDOTHELIAL ACTIVATION 
4.3.1. Growth factor dependent activation of SHP-2 
Having found that SHP-2 seems to have an eminent role in the endothelial 
angiogenic response, it was of interest to elucidate what pathways could have been 
involved in the SHP-2 dependent response. To do so, we concentrated on the 
signalling induced by the three potent angiogenic factors VEGF-A165, bFGF and 
PDGF-BB. As SHP-2 has been shown to function as both a tyrosine phosphatase but 
also as an adaptor molecule, we first measured the phosphatase activity of SHP-2 in 
primary endothelial cells after stimulation with VEGF-A165, bFGF and PDGF-BB 
respectively (Fig. 3.6). All three growth factors were shown to significantly induce 
SHP-2 phosphatase activity, with PDGF-BB being the strongest stimulus. This was 
not surprising, as several others have shown that SHP-2 enhances its phosphatase 
activity upon PDGF stimulation and that this activity is associated with a tyrosine 
phosphorylation of SHP-2 74,140,141. We could also show that PDGF-BB stimulation of 
endothelial cells led to a slighty increased phosphorylation of the tyrosine residue 
542 on SHP-2 (Fig. 3.6 upper part). SHP-2 has been shown to directly interact with 
the VEGF-R2 89 and to become tyrosine phosphorylated upon VEGF-A stimulation 
but a tyrosine phosphorylation of SHP-2 does not necessary enhance its 
activation 142 and no study regarding its activity upon addition of VEGF-A has before 
been performed. In this study, VEGF-A165 stimulation also resulted in an increased 
tyrosine phosphorylation (Y 542) of SHP-2 which correlates well with the measured 
increase in phosphatase activity. Stimulation with bFGF, however, slightly enhanced 
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the SHP-2 phosphatase activity but intriguingly enough, we could not detect a 
phosphorylation of Y 542. It rather seemed to be a dephosphorylation in comparison 
to untreated cells. Kontaridis et al. showed that bFGF induced tyrosine 
phosphorylation of SHP-2 in myoblasts and that the catalytic activity of SHP-2 was 
essential for sustained bFGF dependent ERK activation 95. The difference between 
these two studies is that Kontaridis et al. used an antibody detecting unspecific 
phosphorylated tyrosines, whereas we used an antibody directed against a specific 
tyrosine residue on SHP-2. It may well be that SHP-2 is tyrosine phosphorylated 
upon bFGF stimulation, but not on tyrosine residue 542. One hypothetical 
explanation for the dephosphorylation of Y 542 upon bFGF stimulation may be that 
SHP-2 functions in the first place as an adaptor molecule under bFGF rather than a 
phosphatase and that the dephosphorylation of Y 542 is necessary for releasing the 
binding pocket of one of the SH2-domains to enable the binding to other tyrosine 
phosphorylated molecules (See Fig 1.5 for mechanisms of SHP-2 activation). This 
would also explain the small increase in phosphatase activity measured after 
application of bFGF. The decrease in tyrosine phosphorylation of SHP-2 upon bFGF 
stimulation may also be time dependent. Our experiments were performed by 
stimulation with growth factors for 10 minutes; a shorter stimulation might give a 
different result.  As the SHP-2 activity after VEGF-A stimulation was of a similar 
extent as to bFGF stimulation; it is likely that SHP-2 functions as an adaptor molecule 
also in VEGF-A signalling. The phosphorylated Y 542 may in this case serve as a 
binding site for other SH2-domain containing molecules. The hypothesis that SHP-2 
also can function merely as an adaptor molecule in some cases is supported by a 
study where deletion of the N-terminal SH2-domain, responsible for binding of Tyr(P) 
residues, abrogated EGF induced Akt phosphorylation 98. Taken together, the results 
obtained here indicate that the angiogenic growth factors bFGF, PDGF-BB and 
VEGF-A are able to enhance SHP-2 phosphatase activity, although to different 
extents. 
 
4.3.2. The role of PI3-Kinase in SHP-2 signalling 
The PI3-Kinase / Akt signalling pathway seems to be very important for many 
processes in endothelial cells. For instance, endothelial migration induced by bFGF 
and VEGF was impaired when the PI3-Kinase was inhibited with a pharmacological 
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inhibitor. In addition, FGF and VEGF induced DNA synthesis was decreased when 
PI3-Kinase was inhibited. Furthermore, PI3-Kinase was shown to be important for the 
long term stability of endothelial tubes in a collagen gel  as well as for FGF and 
VEGF induced angiogenesis in the chorioallantoic membrane (CAM) assay 50,51. 
However, somewhat contradicting results exist about the SHP-2 dependent 
regulation of PI3-Kinase. Upon EGF stimulation, SHP-2 has been demonstrated to 
both positively 98 and negatively regulate PI3-Kinase activity in fibroblasts 99,143. 
Whereas several studies exist showing a positive role of SHP-2 in PDGF enhanced 
PI3-Kinase activity 96,99, it had been unknown so far if SHP-2 affects bFGF and 
VEGF-A induced PI3-Kinase activity. It was therefore of interest to investigate the 
effects of SHP-2 on PI3-Kinase and Akt signalling in endothelial cells upon bFGF, 
PDGF-BB and VEGF-A stimulation. All three growth factors enhanced the activation 
of PI3-Kinase in endothelial cells, as shown by tyrosine phosphorylation of the p85 
subunit of PI3-Kinase (Fig. 3.11). This was not surprising since it is known that these 
factors activate the PI3-Kinase and that it is involved in signalling initiated by these 
growth factors 40,50,85. When silencing SHP-2 the PDGF-BB dependent activity of 
PI3-Kinase tended to be diminished as expected. Treatment of endothelial cells with 
bFGF and VEGF-A respectively after SHP-2 knock-down also showed a tendency 
towards a decrease in PI3-Kinase activity. These results indicated that SHP-2 is a 
positive regulator of bFGF and VEGF-A induced PI3-Kinase activity, in addition to 
PDGF-BB induced PI3-Kinase activation. In addition, when investigating the 
activation of Akt, the downstream target of PI3-Kinase which has been implicated in 
most of the cell survival functions of the PI3-Kinase pathway, the bFGF and 
PDGF-BB induced Akt activity was reduced upon SHP-2 AS-ODN treatment 
(Fig. 3.13). This implies that endothelial bFGF and PDGF-BB stimulated Akt 
activation probably is dependent on SHP-2. Intriguingly, VEGF-A stimulation of Rdm 
ODN treated cells failed to induce Akt phosphorylation. This was confusing as 
stimulation of non transfected cells with VEGF-A gave rise to an enhanced Akt 
phosphorylation. It is unlikely, though, that this inability of Rdm ODN treated cells to 
induce VEGF-A dependent activation of Akt is caused by the transfection itself, since 
Rdm ODN transfected cells showed an increase in the VEGF-A dependent 
phosphorylation levels of p85, Raf and ERK1/2. Nevertheless, there are, to our 
knowledge, no data concerning the role of SHP-2 in VEGF dependent PI3-Kinase / 
Akt signalling and our findings indicate that SHP-2 is needed for VEGF induced 
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PI3-Kinase activation but leaves the question whether SHP-2 is necessary for VEGF 
induced Akt activation open. 
 
On the other hand, bFGF has repeatedly been shown to be responsible for 
PI3-Kinase and Akt activation 50,51. Our data show, for the first time, that SHP-2 acts 
upstream of the PI3-Kinase and Akt in endothelial cells upon bFGF stimulation 
thereby positively regulating this pathway. Klinghoffer et al. found that a mutant 
PDGF-R, which in addition to binding PI3-Kinase also bound SHP-2, was able to fully 
activate the PI3-Kinase 55. Furthermore, both PDGF induced PI3-Kinase and Akt 
activity was reduced in mouse fibroblasts which contained a non functional SHP-2 98. 
These studies support our data that, in addition to bFGF, PDGF induced activation of 
the PI3-Kinase and its downstream target Akt is regulated by SHP-2. Furthermore, 
our findings point to a positive role of SHP-2 in bFGF, PDGF-BB and VEGF-A 
dependent PI3-Kinase activation in endothelial cells as opposed to an inhibitory role 
as in the case of EGF 97-99. 
 
SHP-2 is believed to be able to mediate its signalling effects in both catalytic-
dependent and independent ways 72. There are data describing a SHP-2 catalytic 
dependent activation of PI3-Kinase after IGF stimulation in fibroblasts cells 97. 
Interestingly, whereas mutations in the N-SH2 domain of SHP-2 led to a decreased 
EGF dependent Akt activation, mutations in the phosphatase domain rendering 
SHP-2 catalytically inactive enhanced the EGF dependent Akt activation 98. This 
would suggest that SHP-2 is able to, by functioning both as an adaptor protein and 
as a phosphatase, induce two opposed signalling effects, which in turn may explain 
the different observations made concerning EGF dependent PI3-Kinase activity and 
SHP-2. SHP-2 has also been found to associate with p85 after EGF stimulation in 
glioblastoma cells 98 and it is suggested that SHP-2 and p85 exist in a larger 
signalling complex but whether SHP-2 in this case functions merely as an adaptor 
molecule is not clear. The possible adaptor role of SHP-2 will be further discussed 
below (section 4.3.4). 
 
Taken together, it is likely that SHP-2 mediates parts of its angiogenic effects through 
the regulation of the anti-apoptotic and proliferation inducing PI3-Kinase / Akt 
pathway. These findings are supported by data showing a role for SHP-2 in IGF-1 
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stimulated PI3-Kinase activation and caspase-3 induced apoptosis in fibroblasts 97,98. 
The observations made so far in this study strengthen the hypothesis, that SHP-2 
influences anti-apoptotic pathways in human endothelial cells. 
 
4.3.3. Involvement of SHP-2 in the endothelial Raf-MEK-ERK 
pathway  
It is known that the MAP-Kinase pathway (Raf-MEK-ERK) strongly affects the 
angiogenic process by preventing apoptosis and favouring proliferation 57-59. We also 
observed this in our assays, as both endothelial cell proliferation and the ability to 
cover a wound incision in a confluent cell layer was impaired when Raf-1 was 
inhibited with a pharmacological inhibitor (Fig. 3.14). In both these assays, bFGF 
seemed to have the highest protective effect, as a loss in cell number was seen first 
after 72 hours when measuring the MTT reduction, while PDGF stimulated cells 
treated with the Raf-1 inhibitor started to show a decline in cell number already after 
48 hours. Likewise was the wound healing ability in vitro of endothelial cells more 
severely affected in cells treated with the Raf-1 inhibitor together with either 
PDGF-BB or VEGF-A in comparison to cells treated with the Raf-1 inhibitor and 
bFGF. This difference may be explained by the fact that VEGF-A and bFGF, 
although being responsible for similar functions in most cases such as endothelial 
proliferation and survival, stimulate the expression of different genes regulating cell 
growth, survival, migration, apoptosis and oxidative stress 137. Moreover, as 
described earlier, although being endothelium specific, VEGF-A does not seem to be 
the most potent inducer of endothelial dependent processes 57,137. Furthermore, 
according to our results, in our assays bFGF stimulation of the Raf-MEK-ERK 
pathway may be important for endothelial cell proliferation in the first place, as 
stimulation with bFGF led to a higher increase of proliferation rate than PDGF-BB 
(Fig. 3.14A and 3.14B). PDGF induction of this pathway, on the other hand, seemed 
to influence the survival of endothelial cells rather than the proliferation, since the 
wound healing in vitro was impaired already after 24 hours following treatment with 
the Raf-1 inhibitor and was kept at a lower level at all times in comparison to cells 
treated with the Raf-1 inhibitor in the presence of bFGF (Fig. 3.14C). This hypothesis 
is supported by a study performed by Sano et al., who found that a blockage of the 
PDGF-Rβ induces endothelial apoptosis 37. Moreover, recent data showing an 
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increased apoptosis amongst tumour-associated endothelial cells upon inhibition of 
the PDGF-R further supports this hypothesis 144. On the contrary, there are numerous 
studies confirming the role of PDGF in both endothelial cell survival and 
proliferation 33,35,37, although it is not elucidated through which pathways these effects 
are transduced. In the case of bFGF, previous studies have shown that bFGF is a 
strong inducer of endothelial cell proliferation 13. Finally, bFGF induces the 
expression of adhesion molecules, such as the αvβ3 integrin, on the endothelial cell 
surface 145, which may facilitate wound repair, strongly supporting its role in primarily 
cell proliferation. On the other hand, Alavi et al. showed that VEGF and bFGF 
induced Raf activation was important for the prevention of apoptosis 56. Nevertheless, 
the bFGF, PDGF-BB and VEGF-A activation of the Raf-MEK-ERK pathway seems to 
be a possible candidate for the SHP-2 regulated angiogenic response and was 
therefore investigated further.  
 
To elucidate the role of SHP-2 in the Raf-MEK-ERK pathway in endothelial cells and 
to address the question if SHP-2 influences pathways activated during the 
angiogenic process, cells were treated with SHP-2 AS-ODN followed by stimulation 
with bFGF, PDGF-BB and VEGF-A. The phosphorylation of ERK1/2 was used to 
measure the activation of the Raf-MEK-ERK pathway. SHP-2 AS-ODN treatment 
decreased bFGF, PDGF-BB and VEGF-A induced ERK1/2 phosphorylation 
(Fig. 3.16), indicating that SHP-2 is required for Raf-MEK-ERK activation under the 
influence of all of these growth factors. Another protein able to activate this pathway 
is the protein kinase C (PKC) 7,62. Activation of PKC through stimulation with PMA 
has been shown to induce a strong ERK1 activation. This activation was not affected 
by SHP-2 deficiency in mouse fibroblasts 146. Therefore, we chose this approach to 
test whether the effect seen on the decreased ERK1/2 phosphorylation by the 
AS-ODN was specific and not an effect secondary to apoptosis. A robust ERK1/2 
phosphorylation upon PMA stimulation of SHP-2 AS-ODN treated endothelial cells 
could be observed, confirming that the reduction in ERK1/2 activation in these 
experiments was specific for the inhibition of the Raf-MEK-ERK pathway by SHP-2 
AS-ODN (Fig. 3.17).  
 
As we could detect marked deficiencies in the activation of the Raf-MEK-ERK 
pathway following SHP-2 AS-ODN treatment, it was of significance to investigate if 
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there may be a factor directly connecting the two. Inhibition of PI3-Kinase with 
Wortmannin inclined a diminished bFGF, PDGF-BB and VEGF-A induced Raf-1 and 
ERK1/2 phosphorylation (Fig. 3.15). This led to the assumption that PI3-Kinase does 
not only function to activate Akt, but also activates the Raf-MEK-ERK pathway 
promoting endothelial cell survival and proliferation. Furthermore, our findings 
demonstrate that SHP-2 regulates bFGF, PDGF-BB and VEGF-A dependent ERK1/2 
activation probably through PI3-Kinase. 
 
Several studies showing an involvement of SHP-2 in MAP-Kinase signalling exists. 
For instance, Tang et al. found SHP-2 to function upstream of the Raf-MEK-ERK 
pathway in FGF signalling being important for mesoderm induction in Xenopus 88. 
Furthermore, Shi et al. 146 showed that SHP-2 was required for PDGF and IGF 
induced ERK1 activation in mouse fibroblasts. However, this is the first time SHP-2 
has been demonstrated to be important for angiogenic factor dependent activation of 
the Raf-MEK-ERK pathway in human endothelial cells. Furthermore, VEGF is one of 
the best described factors inducing Raf-MEK-ERK activation, but never before has 
SHP-2 been described as an essential link between VEGF and the Raf-MEK-ERK 
signalling cascade.  
 
While Zhang et al. 93 suggest that SHP-2 controls ERK activation through Src family 
kinase activation thereby involving PLCγ and Ras induced ERK activation, Cunnick´s 
et al. have found, in addition to regulating Src kinase, that a binding of SHP-2 to the 
Grb 2-associated binder 1 (Gab-1) is necessary for an adequate ERK activation 92 . 
Our findings are supported by these data and furthermore introduce a new possible 
target for SHP-2, namely PI3-Kinase, for the activation of ERK1/2 in endothelial cells. 
 
 
4.3.4. The target of SHP-2 in bFGF, PDGF-BB and VEGF-A 
dependent endothelial signalling 
Such central position of SHP-2 in the regulation of endothelial cell viability points the 
question towards the potential direct target of SHP-2 in influencing these anti-
apoptotic pathways. As PI3-Kinase was shown to regulate both ERK1/2 and Akt 
activation in endothelial cells in the previous experiments and the fact that the p85 
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subunit is tyrosine phosphorylated, in order to activate the enzyme, we hypothesized 
that PI3-Kinase may be the direct target coupling SHP-2 to Akt and ERK1/2 
activation and thus may also be the link between SHP-2 and its proliferative and anti-
apoptotic effects observed in this study. Indeed, we observed a bFGF, PDGF-BB and 
VEGF-A dependent association of the p85 subunit of PI3-Kinase with SHP-2 in 
endothelial cells (Fig. 3.17 upper blot). This is in accordance with other studies 
showing an interaction between PI3-Kinase and SHP-2 after IGF stimulation resulting 
in enhanced PI3-Kinase activation in mouse fibroblasts 98. Others have found that the 
Grb 2-associated binder 1 (Gab-1) binds SHP-2 upon EGF, PDGF and bFGF 
stimulation 91,92,99,133 and that this seems to be important for at least EGF and PDGF 
induced SHP-2 dependent signalling 91,92,99. Furthermore Gab-1 has been found to 
bind to the VEGF-R2 in endothelial cells, a receptor to which SHP-2 also was found 
to bind 89. Moreover, Ong et al. 133 found that FGF-1 activated PI3-Kinase and Akt 
through a signalling complex consisting of the FGF-Receptor Substrate 2 (FRS-2), 
Grb 2 and Gab-1. These findings taken together with ours suggest that PI3-Kinase 
and SHP-2 could be involved in the same signalling complex together with for 
instance Gab-1. Indeed, immunoprecipitation of SHP-2 showed an enhanced binding 
of Gab-1 to SHP-2 upon bFGF, PDGF-BB and VEGF-A stimulation (Fig. 3.17 lower 
blot), revealing a possible link between SHP-2 and PI3-Kinase / Akt and MAP Kinase 
signalling in endothelial cells. 
 
Others have reported that SHP-2 regulates ERK1/2 activity through the Src kinase by 
promoting the disassociation of the negative Src-regulator Csk 93,147. Src kinases 
have been found to phosphorylate p85 on a tyrosine residue, thereby inducing the 
activity of the catalytic subunit p110 40,46. We have shown that SHP-2 is necessary 
for this tyrosine phosphorylation in endothelial cells, which suggests that SHP-2 may 
even be upstream of Src kinase. Although the exact mechanism remains to be 
elucidated, one can hypothesize that SHP-2 binds Gab-1 upon growth factor 
stimulation, which brings SHP-2 close to the cellular membrane. SHP-2 may then 
positively influence the activity of Src kinase, which then is able to phosphorylate and 
thereby activate the PI3-Kinase. PI3-Kinase is now able to translocate to the 
membrane, where it binds Gab-1, which brings it in close proximity to its substrate. 
This hypothesis is supported by data showing a decreased binding of the p85 subunit 
to Gab-1 in SHP-2 deficient fibroblasts upon PDGF stimulation, which was 
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associated with a decreased Akt and ERK phosphorylation 99. Interestingly, upon 
EGF stimulation the opposite could be observed by several groups 99,143, showing 
that SHP-2 does not only function as either a positive or negative regulator of 
different pathways but the effect on a particularly pathway is highly dependent on the 
stimulus. For a summary of the role of SHP-2 in the signalling pathways investigated 
in this study see figure 4.1. 
 
 
 
Fig. 4.1 Schematic overview of the mechanisms of SHP-2 function in FGF-2, 
PDGF-BB and VEGF-A dependent endothelial angiogenic signalling 
investigated in this study 
Upon FGF-2 or PDGF-BB stimulation, the p85 subunit of the PI3-Kinase becomes 
tyrosine phosphorylated, which renders the kinase active (p110 subunit). This 
activation seems to be dependent on the presence of SHP-2. Furthermore, SHP-2 
associates with p85 and Gab-1, which indicates that SHP-2, PI3-Kinase and Gab-1 
are parts of the same signalling complex. SHP-2 dependent PI3-Kinase activation 
leads to Akt and Raf-MEK-ERK pathway activation in the case of bFGF and 
PDGF-BB stimulation (left part). VEGF-A application results in only PI3-Kinase 
dependent ERK activation and is independent of Akt activation (right part). SHP-2 
was also shown to be critical for endothelial cell survival, proliferation and migration, 
which are controlled by the PI3-Kinase / Akt and the Raf-MEK-ERK pathway in 
endothelial cells. These processes are necessary for tube formation and subsequent 
vessel sprouting, events which were also influenced by SHP-2 in this study. 
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4.4. LIMITATIONS OF THE STUDY 
While the use of AS-ODN assures a specific and efficient knock-down of the protein 
of interest, it does not in this case give any information about the need for SHP-2 
phosphatase activity in our assays. This would be of interest to investigate, since 
SHP-2 can function both as a phosphatase and as an adaptor molecule. This would 
be possible when using a dominant negative phosphatase mutant of SHP-2. To 
further confirm the results obtained in this study, an over expression of SHP-2 by a 
constitutively active SHP-2 in endothelial cells would be necessary. Both these 
approaches would require the transfection of vectors containing the constructs for the 
SHP-2 mutants into endothelial cells. This could be difficult, as transfer of genes to a 
practically transfection resistant cell type probably either lacks the necessary 
efficiency or is hampered by high toxicity. Retroviral techniques may allow for 
sufficient transfection efficiency without considerable cytotoxicity. 
 
Many but not all experiments were performed with primary HUVEC. In some assays, 
though, we had to rely on HMEC, due to limited access to umbilical cords. Also, 
some of the experiments where a longer time in starvation media (over 12 hours) was 
needed could only be done with HMEC because HUVEC detached themselves from 
the cell culture dish after 12 hours. Although HMEC share many characteristics with 
primary endothelial cells, such as cobblestone morphology in monolayer culture and 
expression of von Willebrand´s factor and form tube like structures in Matrigel 130, it is 
an immortalised cell line and not primary cells. Furthermore, new research shows 
that expression of genes involved in cell differentiation and cell cycle regulation does 
not differ between HMEC and HUVEC, while gene expression regarding cytokines, 
chemokines and cell surface proteins does 148. Therefore one should not always refer 
to endothelial cells of different origins as if they were the same. Some of the 
experiments were performed in primary PAEC. This could only be done when using 
inhibitors, as our AS-ODN did not silence porcine SHP-2. Unfortunately, the porcine 
DNA sequence for SHP-2 was also not available, thus making a SHP-2 AS-ODN 
synthesis directed against porcine SHP-2 a tricky quest. 
 
A general methodological problem regarded the evaluation of western blots. Although 
repeated experiments gave rise to the same results (i.e enhancement or reduction in 
protein phosphorylation levels) it was difficult to mirror this by measuring the protein 
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band densities of the different blots. This yielded a rather large standard error 
deviation (SED) due to variability between the blots caused by differences in the 
cellular expression of the proteins used as loading controls (actin or GAPDH) in the 
different experiments. This in turn made it difficult comparing ratios between actual 
protein band and loading control of different western blots. This variance might have 
been of a minor problem if more experiments (n´s) had been performed, as, 
according to many statistical textbooks, a testing population greater than the ones 
used in these experiments would be required for proper statistical testing. 
 
For a more accurate predication of the effects of SHP-2 knock-down in in vivo, the 
results obtained in this study need to be verified by a direct in vivo model, such as 
the chorioallantoic membrane (CAM) assay or the Matrigel plug assay in mice. The 
CAM-assay, however, would probably not allow for magnet guided transfection of 
SHP-2 AS-ODN or any other constructs, but would have to rely on inhibitors. 
Although it probably would be possible to use transfection techniques with the 
Matrigel plug assay, this could still be troublesome. We experienced difficulties in 
verifying the transfection of a Cy-3 labelled SHP-2 AS-ODN into the endothelium of 
the mouse aorts (used for the aortic ring sprouting model), due to auto-fluorescence 
originating from the mouse itself, and were therefore unfortunately unable to achieve 
a reliable transfection of the aortae with SHP-2 AS-ODN (data not shown).  
 
Although we could show that SHP-2 is needed for endothelial cell survival and that 
SHP-2 involves the activation of the Raf-MEK-ERK and PI3-Kinase / Akt pathways, 
which are important for apoptosis prevention and induction of proliferation in 
endothelial cells, we have not investigated the exact mechanisms of SHP-2 
involvement for these events. Therefore, to further confirm the influence of SHP-2 in 
the Raf-MEK-ERK and PI3-Kinase / Akt pathways in endothelial cells, it would be of 
interest to investigate whether SHP-2 affects the activation of proapoptotic proteins, 
such as Bad, Bax or Caspases, and even the transcription of anti-apoptotic genes as 
well as transcription of genes important for cell cycle progression. 
 
 
 126 
4.5. THERAPEUTIC POTENTIAL AND FUTURE ASPECTS 
The finding that SHP-2 is a positive regulator of angiogenesis may be of interest in 
the development of strategies aiming at controlling this process. For instance, in 
ischemic diseases these events are critical to allow for neovascularization of tissue 
that has suffered from either acute or chronic blood supply loss. An intact 
physiological function of the SHP-2 dependent regulation of the endothelial 
angiogenic response may be a prerequisite for the success of any strategy aiming to 
induce angiogenesis therapeutically. On the contrary, the rate limiting step in tumour 
development is the ability of the tumour to induce its own vascularisation 149. Without 
sufficient blood supply not only is the growth of the tumour inhibited but also the 
tumours´ ability to spread to other sites is limited. A site directed inhibition of SHP-2, 
accomplishing an inability of tumour secreted angiogenic factors such as VEGF-A, 
bFGF and PDGF-BB to activate endothelial cells leading to proliferation and 
ultimately new vessel sprouting, may impair or even inhibit the tumour induced 
angiogenesis. This would dramatically reduce the risk of further tumour growth and 
spreading giving cancer patients a higher chance of survival.  
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5. SUMMARY 
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Angiogenesis is a vital process, which continues throughout life. It is dependent on a 
variety of growth factors, such as basic fibroblast growth factor (bFGF), vascular 
endothelial growth factor (VEGF-A) and platelet derived growth factor BB 
(PDGF-BB), which prevent endothelial cell apoptosis, induce endothelial cell 
proliferation and migration 2 as well as promote the organization of endothelial cells 
into tube-like structures followed by proper vessel sprouting 8. The PI3-Kinase/Akt 
pathway 50,51 and the Raf-MEK-ERK signalling cascade 57 have been shown to be 
eminent for the angiogenic process. A tyrosine phosphatase, involved in the 
regulation of these pathways, is the Src homology 2 domain containing tyrosine 
phosphatase 2 (SHP-2) 72. The role of SHP-2 in functional angiogenesis and in 
endothelial angiogenic signalling, however, is unknown. Using antisense 
oligonucleotide (AS-ODN) magnetofection, a technique where AS-ODNs coupled to 
superparamagnetic nanoparticles are delivered by magnetic force, or a 
pharmacological inhibitor of SHP-2 (Ptp I IV) we investigated the role of SHP-2 in 
angiogenic processes, such as endothelial cell survival, proliferation, tube formation 
and vessel sprouting as well as in VEGF-A, bFGF and PDGF-BB enhanced 
signalling in human microvascular- (HMEC) and umbilical vein endothelial cells 
(HUVEC). 
 
Treatment with PtpI IV resulted in a delayed bFGF and PDGF-BB dependent wound 
healing response, as assessed by a scratch of a confluent cell layer. Only 52±7% 
and 42±5% (both p<0.01, n=3) of the wound incision was covered again after 48 
hours after treatment with PtpI IV together with bFGF and PDGF-BB respectively. Not 
only basal proliferation, as assessed by  MTT reduction, of HMEC was significantly 
inhibited (by 48±5%; p<0.01, n=12) but also bFGF (by 41±5%; p<0.01, n=12) and 
PDGF-BB (by 55±7%; p<0.01, n=12) dependent proliferation in SHP-2 AS-ODN 
treated cells as compared to nonsense (Random) oligonucleotides (Rdm ODN) 
treatment was impeded. This seemed to be due to enhanced apoptosis, because cell 
cycle analysis by propidium iodide staining and Annexin V staining revealed a 
2.4-fold increase in cells detected in the subG0 fraction (p<0.01, n=6) and a 
significant rise in Annexin V positive cells (23±7%; p<0.05; n=8) following SHP-2 
AS-ODN treatment compared to Rdm ODN treatment. Moreover, cells lacking a 
functional SHP-2 exhibited a lower number of capillary-like structures in 
proangiogenic Matrigel (SHP-2 AS-ODN: p<0.01, n=8; PtpI IV: p<0.05, n=3). In 
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addition, when treating aortic rings embedded in Matrigel with the pharmacological 
SHP-2 inhibitor, sprouting of new vessels from the aortic rings was impeded by 
55±12% (p<0.05; n=10). Furthermore, SHP-2 knock-down inclined a decreased 
bFGF, PDGF-BB and VEGF-A induced phosphorylation of the PI3-Kinase regulatory 
subunit p85 (n=2-3). The bFGF and PDGF-BB induced Akt phosphorylation was also 
diminished (n=6 and n=5, p<0.05 and p<0.01 respectively), whereas the VEGF-A 
induced Akt activation remained unaffected (n=4). Furthermore, SHP-2 AS-ODN but 
not Rdm ODN transfection led to a diminished bFGF (n=7, p<0.05)-, PDGF-BB (n=5, 
p<0.05)- and VEGF-A (n=5, p<0.05) dependent phosphorylation of the MAP Kinase 
ERK 1/2 but not treatment with the protein kinase C stimulator PMA (n=4). Moreover, 
the growth factor induced ERK 1/2 and Raf-1 activation was suppressed by the 
PI3-Kinase inhibitor Wortmannin. Lastly, bFGF-, PDGF-BB- and VEGF-A stimulation 
of endothelial cells led to a direct interaction between SHP-2, p85 and the Grb 
associated binder-1 (Gab-1) (n=3).  
 
Our results indicate that SHP-2 is necessary for processes involved in angiogenesis, 
such as endothelial cell survival, bFGF and PDGF-BB dependent endothelial wound 
healing in vitro and cell proliferation. Moreover, SHP-2 is involved in tube formation 
and vessel outgrowth. Finally, SHP-2 regulates angiogenic growth factor dependent 
activation of the PI3-Kinase/Akt pathway as well as the MAP kinase pathway in 
endothelial cells probably by forming a signalling complex with Gab-1 and 
PI3-Kinase. Thus, our findings may identify SHP-2 as a new angiogenic factor and 
might be of relevance in situations requiring the control of angiogenesis.  
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6.1. ABBREVIATIONS 
aFGF   acidic Fibroblast Growth Factor 
Ang 1 & 2  Angiotensin 1 and 2 
ALL    Acute lymphoblastic leukemia 
AS-ODN  Antisense desoxynucleotide 
bFGF   basic Fibroblast Growth Factor 
CAM   Chorioallantoic membrane 
cGMP   cyclic guanosine monophosphate 
Csw    Corkscrew 
Cy-3    Carbocyanin 
2D/3D   Two dimensional/ three dimensional 
DMSO  Dimethylsulfoxid 
ECM   Extracellular matrix 
EDTA   Ethylenediaminetetraacetic acid 
EGF    Epidermal growth factor 
EPO    Erythropoietin 
ERK   Extracellular signal Regulated Kinase 
FACS   Fluorescent-activating cell scanner 
FAK    Focal adhesion kinase 
FCS   Fetal Calf Serum 
FGFR   Fibroblast Growth Factor Receptor 
Flk   Fms-like tyrosine kinase 
FRS-2  Fibroblast growth factor receptor substrate 2 
Gab-1   Grb-2 associated binder 1 
GM-CSF  Granulocyte macrophage colony stimulating factor 
Grb2   Growth factor Receptor Bound protein 2 
GTPase  Guanosine triphosphatase 
HEPES  N-(2-Hydroxyethyl)piperazine-N´-(2-ethanesulfonic acid) 
HMEC  Human microvascular endothelial cells 
HUVEC  Human Umbilical Vein Endothelial Cells 
IAPs    Inhibitor of apoptosis proteins 
ICAM-1  Intercellular adhesion molecule 1 
IDDM   Insulin dependent diabetes mellitus 
IGF    Insulin like growth factor 
IKK    Inhibitor of nuclear factor kappa-B kinase 
IL    Interleukin  
IRS-1   Insulin receptor substrate 1 
JMML   Juvenile myelomonocytic leukemia 
kDa    Kilo Dalton 
KDR   Kinase-insert Domain-containing Receptor 
LS    LEOPARD syndrome 
MAPK   Mitogen Activated Protein Kinases 
MAPKK  Mitogen activated protein kinase kinase 
MAPKKK  Mitogen activated protein kinase kinase kinase 
MEK   MAPK/ERK kinase 
Met    Methionine 
MTT    Methylthiazoletetrazolium 
NBCS   Newborn Calf Serum 
NFκB   Nuclear factor kappa-B 
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NIDDM  Non insulin dependent diabetes mellitus 
NO    Nitric oxide 
NS    Noonans syndrome 
PAEC   Porcine endothelial cells 
PAK    p21 activated kinase 
PBS   Phosphate Buffered Saline 
PDGF   Platelet Derived Growth Factor 
PDGFR  Platelet derived growth factor receptor 
PDK1 & 2  3-phosphoinositide-dependent protein kinase 1 & 2 
PECAM-1  Platelet endothelial cell adhesion molecule 1 
PEI   Polyethylenimine 
PI    Propidium iodide 
PI3-Kinase  Phosphoinositide 3-Kinase 
PI(3,4,5)P3  phosphatidylinositol-3,4,5-triphosphate 
PI(4,5)P2  phosphatidylinositol-4,5-triphosphate 
PKA    Protein kinase A 
PKC   Protein Kinase C 
PLCγ   Phospho Lipase Cγ 
PMA   Phorbol-myristate-acetate 
pNPP   p-Nitrophenyl phosphate 
PTGS   Posttranscriptional gene silencing 
PTK    Protein tyrosine kinase 
PTP    Protein tyrosine phosphatase 
Ptp I IV  Protein tyrosine phosphatase inhibitor IV 
Ptpn11  Gene coding for SHP-2 
pTyr   Phosphorylated tyrosine 
Rdm ODN  Random desoxynucleotide 
RISC   RNA Induced Silencing Complex 
RNAi   RNA interference 
SDS   Sodeum dodecyl sulfate 
siRNA   short interfering RNA 
SH3    Src- homology 3 
SHP-1  Src homology 2 domain containing tyrosine phosphatase 1 
SHP-2  Src homology 2 domain containing tyrosine phosphatase 2 
Sos   Son Of Sevenless 
TGFβ   tumour necrosis factor β 
u-PA   urokinase-type plasminogen activator 
VE-Cadherine Vascular endothelial Cadherin 
VEGF   Vascular Endothelial Growth Factor 
VEGFR  Vascular Endothelial Growth Factor Receptor 
VPF   Vascular permeability facto 
VVO   Vesiculo-vacuolar organelles 
Y542/Y580  Tyrosine residue in position 542/580 respectively 
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Lectures 
 
Inhibition of SHP-2 prevents human endothelial cell proliferation by inducing 
apoptosis 
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Inhibition of SHP-2 prevents human endothelial cell proliferation and induces 
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